University of Texas Medical Branch at Galveston, Departments of Internal Medicine, Physiology, and Biophysics and Pathology, Galveston, Texas 77555-0567
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Intestinal
subepithelial myofibroblasts (ISEMF) and the interstitial cells of
Cajal are the two types of myofibroblasts identified in the intestine.
Intestinal myofibroblasts are activated and proliferate in response to
various growth factors, particularly the platelet-derived growth factor
(PDGF) family, which includes PDGF-BB and stem cell factor (SCF),
through expression of PDGF receptors and the SCF receptor
c-kit. ISEMF have been shown to play
important roles in the organogenesis of the intestine, and growth
factors and cytokines secreted by these cells promote epithelial restitution and proliferation, i.e., wound repair. Their role in the
fibrosis of Crohn's disease and collagenous colitis is being
investigated. Through cyclooxygenase (COX)-1 and COX-2 activation, ISEMF augment intestinal ion secretion in response to certain secretagogues. By forming a subepithelial barrier to
Na+ diffusion, they create a
hypertonic compartment that may account for the ability of the gut to
transport fluid against an adverse osmotic gradient. Through the
paracrine secretion of prostaglandins and growth factors (e.g.,
transforming growth factor-), ISEMF may play a role in
colonic tumorigenesis and metastasis. COX-2 in polyp ISEMF may be a
target for nonsteroidal anti-inflammatory drugs (NSAIDs), which
would account for the regression of the neoplasms in
familial adenomatous polyposis and the preventive effect of NSAIDs in
the development of sporadic colon neoplasms. More investigation is
needed to clarify the functions of these pleiotropic cells.
interstitial cells of Cajal; cyclooxygenase; chemoprevention; wound repair; fibrosis; electrolyte transport; immunophysiology
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
FUNDAMENTAL BIOLOGICAL PROCESSES such as cell motility, proliferation, differentiation, apoptosis, morphogenesis, tissue repair, inflammation, and the immune response are initiated, maintained, and terminated by local interactions between cells. These interactions are brought about by contact of cells with each other or with the extracellular matrix (ECM) or through the elaboration of and response to soluble mediators. Although myofibroblasts were identified morphologically a century ago, it is now recognized that they constitute a family of paracrine cells that play an important role in the regulation of these fundamental processes [see part I of this review, which appeared in the July issue (163)] (181, 207). This article focuses on intestinal subepithelial myofibroblasts (ISEMF), the most recently recognized myofibroblasts in the intestine, with a brief review of the interstitial cells of Cajal (ICC), the other intestinal myofibroblasts.
The ICC are located in the submucosa and muscularis propria in association with the smooth muscle layers of the gut. The ISEMF are located in the lamina propria under the epithelial cells. It is not known if these two myofibroblasts are derived from a common precursor (stem) cell. Both exist as a syncytium, but it has not been determined whether the ICC network is physically connected to the ISEMF network. The ICC was discovered over 100 years ago and 50 years ago was shown convincingly not to be a specialized neuron but a fibroblast-like cell (176). Twenty years ago these cells were proposed to be the electrical pacemakers that control motility of the gastrointestinal tract, and recently a large body of evidence affirms this concept (176). Over 30 years ago Pascal, Kaye, and Lane (148) described a sheath of lamina propria fibroblasts in tight apposition to the crypts in the intestine. This structure was confirmed by others and was found also in other gastrointestinal tissue, such as the gallbladder and stomach (70, 95, 100, 101, 110, 111, 127, 133, 178). This fibroblastic sheath or pericryptal cells (fibroblasts), as they were called then (178), are now known to be a syncytium of cells that extend throughout the lamina propria (95).
![]() |
ICC |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Morphologically, the ICC have the classic appearance of myofibroblasts and exist in several separate locations within the gastrointestinal tract (84, 176). Classically, they are located in the intermuscular space between the circular and longitudinal layers of the muscularis propria in the stomach, small bowel, and colon. However, they also reside, with slight differences in morphology, along the submucosal surface of the circular muscle bundles of the colon, within the deep muscular plexus region of the small intestine, and intramuscularly in the esophagus, stomach, and colon (176, 199). These cells have a stellate appearance and are connected in a syncytium via gap junctions (31, 110). They have all the morphological characteristics of myofibroblasts [see part I of this review (163) as well as Ref. 205]. The biology of ICC has been reviewed excellently and in detail by Sanders (176), a review with many original references not listed here.
Antibodies against the receptor c-kit localize ICC in the mouse embryo (220) and suggest that the ICC originate from the mesenchyme of the gut and not from neural crest cells, the precursors of intestinal neurons (10, 201, 229). However, the true origin of these cells is still uncertain. The embryonal cells responsible for the synthesis and secretion of stem cell factor (SCF), the ligand that promotes the growth and differentiation of c-kit-positive ICC, have also not been clearly identified (209).
Considerable experimental evidence suggests three major functions of the ICC: 1) they are pacemakers for gastrointestinal smooth muscle motility, 2) they facilitate active propagation of electrical events, and 3) they modulate neurotransmission (176). As myofibroblasts, it is likely, however, that they have other functions [see part I of this review (163)], such as immune modulation, growth, repair, and fibrosis. These additional functions should be investigated in ICC.
The mammalian intestine demonstrates a wave of electrical activity with a characteristic frequency somewhere between 6 and 12 cycles per minute, depending on the segment studied (85, 176). These slow waves are accompanied by corresponding peristaltic contractions during the intercibal periods, and this activity is thought to serve a housekeeper function of clearing the intestinal lumen between meals. The pattern is disrupted by eating. Both freshly isolated and cultured ICC demonstrate oscillations of membrane potential due to varying Ca2+ conductivity, i.e., activation or closure of voltage-dependent Ca2+ channels (176). This property constitutes the primary evidence for assigning the pacemaker role to the interstitial cells (see Ref. 176 for original references). The lack of propagation of the slow wave in the bulk of smooth muscle, plus the fact that removing a thin strip of tissue that contains the syncytium of ICC also destroys the intestinal slow-wave activity, give strong credence to the idea that the ICC syncytium is the origin of the slow wave. Furthermore, chemical lesions of the ICC also inhibit both the pacemaker potentials and slow-wave propagation.
Evidence that ICC are involved in neurotransmission is both anatomic (their intermediate position between neural varicosities and the smooth muscle cells) and physiological. ICC are responsive to a host of enteric neurotransmitters, including acetylcholine, nitric oxide, vasoactive intestinal peptide, ATP, and substance P (176). Nitric oxide and, recently, carbon monoxide have been proposed as inhibitory neurotransmitters generated by the ICC and other myofibroblasts (8, 57, 131, 136).
Additional evidence for a pacemaker role of ICC comes from experiments using antibodies directed against c-kit protein (85, 200). When neutralizing c-kit (ACKII) antibodies are injected in neonatal animals for several days following birth, intestinal c-kit immunoreactivity disappears and intestinal smooth muscle activity becomes abnormal (85, 144, 200). Furthermore, the electrical rhythmicity of the embryo and neonate is absent until c-kit-positive cells appear (201).
Mutants of c-kit expression clarify the function of ICC (85, 90, 176). The white-spotting (W) locus in mice and a hypopigmentation disorder in humans known as piebaldism are allelic with c-kit. A number of spontaneous mutations of the W locus are available, which either completely or partially block c-kit protein expression. Mutations that completely block expression of c-kit are fatal; homozygotes (W/W) die in utero. However, there are point mutations of the locus, such as Wv, that do not completely abolish the receptor expression. Wv/Wv homozygotes or compound W/Wv heterozygotes lose electrical slow-wave rhythmicity and have abnormalities of intestinal smooth muscle function. Humans born with piebaldism often develop congenital megacolon.
Mutants of SCF, so-called Steel mutants, also clarify the role of the ICC in gut motility (176). The classic Steel (Sl) mutants represent a complete deletion of the genomic region that codes for SCF, and homozygotes (Sl/Sl) do not survive because of development of severe anemia. However, nonlethal mutants such as Sl-dickie (Sld) and compound heterozygotes such as Sl/Sld retain some c-kit signaling activity (16). The ICC of these animals are histologically abnormal, and their electrical and contractile patterns of the intestinal smooth muscle are abnormal as well (217).
The recognized human diseases associated with abnormalities of the ICC are diseases of gastrointestinal motility and inflammation (84): congenital megacolon of piebaldism and Hirschsprung's disease (176, 209), infantile hypertrophic pyloric stenosis (208), intestinal pseudoobstruction (18, 84, 89), possibly achalasia (218), and ulcerative colitis (173). Hirschsprung's is a polygenic disease that results in enteric nervous system aganglionosis and disturbed motility. Mutant genes associated with Hirschsprung's disease include 1) the RET protooncogene, a tyrosine kinase receptor, which prevents ganglion cell migration from the neural crest (151); 2) the endothelin-3 (ET-3) gene (172); and 3) the gene for the ET-3 receptor (172). The ICC in Hirschsprung's disease are present, but morphologically abnormal, indicating that disturbed ICC function accompanies aganglionosis in this polygenic disease (176, 209). Perhaps the presence of ICC is required for the migration and full development of ganglionic neurons (115) (or vice versa) or, alternatively, some defect in the embryological mesenchyme affects both the migration of neural crest cells and the differentiation of the ICC.
Infantile hypertrophic pyloric stenosis is a relatively common disease of newborns, characterized by hypertrophy of the muscular region of the pyloric sphincter (208). Various pathological disturbances have been demonstrated, including abnormalities of the enteric nervous system and, more recently, the reduction or lack of the neuronal isoform of nitric oxide synthase. c-Kit immunoreactive ICC have been shown to be absent in the longitudinal muscle layer and in most of the hypertrophic muscle of all 26 patients investigated (208). The exact role of the ICC in the muscular abnormality of this disease is unclear.
Recently, abnormalities in nitric oxide-dependent inhibitory neurotransmission in the lower esophageal sphincter (LES) of W/Wv mutant mice raise the interesting possibility of a role of the ICC in human achalasia, a disease in which the LES fails to relax (218). This work needs to be confirmed and extended in the human disease.
Abnormalities of the colonic ICC at an ultrastructural level have been demonstrated in patients with severe ulcerative colitis (173). The role these abnormalities may play in the deranged motility of colonic inflammation remains to be defined. It is possible that the histological abnormalities of the ICC in ulcerative colitis might be secondary to high-dose corticosteroid therapy rather than the inflammation. Glucocorticoids decrease the number of tissue mast cells (also c-kit-positive cells) by downregulating the amount of SCF produced by fibroblasts (55). Therefore, reductions in the amount of available SCF could result in histological abnormalities and even apoptosis of the ICC.
![]() |
ISEMF |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ISEMF exist in a subepithelial location throughout the gastrointestinal
tract from esophagus to anus and in the gallbladder and pancreas, but
they are best described in the small intestine and colon (70, 95, 100,
101, 111, 148). Although initially thought of as a sheath of
fibroblasts, more dense in the region of crypts than at the surface of
the colon or in the villi of the small intestine (70, 100, 127, 148),
it is now clear that they exist as a syncytium that extends throughout
the lamina propria of the gut, merging with the pericytes surrounding
the blood vessels that course through the tissue (95). In the region of
the crypts, the myofibroblasts are oval and scaphoid in appearance and
appear to overlap like shingles on a roof (100, 137). Even here they
are attached one to the other with both gap junctions and adherens
junctions, as they are throughout the syncytium. In the upper regions
of the colonic crypts and in the small intestinal villi, the ISEMF take
on a stellate morphology (Fig.
1) (95, 111, 207).
|
Ultrastructural studies demonstrate close contacts between ISEMF and synaptic vesicle-containing nerve terminals (70). We have found that 18Co colonic myofibroblasts contain carbachol receptors coupled to prostaglandin (PG) E2 synthesis and reversal of stellate transformation (77, 205). These data suggest that ISEMF can be modulated by cholinergic inputs, and structures resembling dendritic spines on stellate 18Co processes may be the location of these acetylcholine receptors (205).
At transmission electron microscopic resolution, ISEMF have the typical appearance of myofibroblasts: a cell membrane with multiple caveolae, a well-developed rough endoplasmic reticulum and Golgi complex, and a cytoplasm filled with microfilament bundles (stress fibers) and associated dense bodies [see part I of this review (163) and Ref. 205]. In the small intestinal villus, the processes of the ISEMF are even more attenuated and encircle the capillaries that extend throughout the lamina propria (111). Here ISEMF are essentially indistinguishable from pericytes (35) (and indeed may be one and the same).
The basal lamina contains numerous fenestrations, particularly on the upper two-thirds of the villus, and cell processes of the myofibroblasts and/or the epithelium can extend through these fenestrae (100, 111, 202). The myofibroblasts are embedded also in a subepithelial sheet of reticular fibers that also contains fenestrae or foramina through which lymphocytes and macrophages traverse (202). Just below the surface epithelium of the colon, the reticular sheet is called the collagen table. Processes of the myofibroblasts extend through this table and abut the basal lamina under the surface epithelial cells with foot processes reminiscent of those in the kidney glomerulus (100, 148). Thus the subepithelial space appears to have two fenestrated barriers: the basal lamina and the subepithelial reticular sheet in the small intestine (or collagen table in the colon), both of which are formed by connective tissue fibrils secreted by the myofibroblasts. This anatomic feature may have functional implications for water transport by the epithelium (see Water and Electrolyte Transport).
Antibodies that react against -smooth muscle (
-SM) actin or
against glial fibrillary acidic protein will stain ISEMF as well as
ICC, hepatic stellate cells, pancreatic stellate cells, and other
stellate-type myofibroblasts such as those in Wharton's jelly of the
umbilical cord [see part I of this review (163) and Ref.
61]. The identifying cytoskeletal staining characteristic of
ISEMF, however, is their reaction to
-SM actin antibodies. ISEMF can
be distinguished from smooth muscle of the muscularis mucosae, which is
also
-SM actin positive, by absence of staining for desmin (Fig.
2) (129, 165, 166). Thus both ISEMF and
muscularis mucosae stain for
-SM actin and variably for myosin, but
the ISEMF, in contradistinction to the muscularis mucosae, is negative (normal intestine) or only weakly positive (severely inflamed intestine) for desmin (129, 165, 166, and A. B. West, unpublished observations).
|
Several independent studies in mice reveal the presence of ICC, as
determined by c-kit expression, in the
embryo from days 12.5-13.5 onward
(10, 176, 199, 220). With the use of -SM actin as a marker, ISEMF in
the human embryo are detectable in the intestine at 21 wk of gestation
(178). The origin of these cells may be from the neural tubes or neural
crest stem cells, migrating along the vagus nerve to the gut (14, 92).
Alternatively, ISEMF may transdifferentiate from resident fibroblasts
or smooth muscle cells [see part I of this review (163)].
The cells are first visible in immediate juxtaposition with the
muscularis mucosae at the base of the intestinal crypts (97). Between
the 21st and 39th wk, the number of ISEMF increases progressively in
the region between the base and the middle of the crypts, in synchrony with the proliferation and differentiation of the epithelial cells. At
birth, the ISEMF line the lower two-thirds of the crypts of the colon,
and all of the cells avidly express
-SM actin. These studies suggest
that antibodies against
-SM actin are currently the best markers for
ISEMF and, furthermore, that ISEMF may originate from the muscularis
mucosae or from cells adajcent to them. It is important to note that
c-kit antibody staining, which defines the ICC, has not been studied extensively in ISEMF and, conversely,
-SM actin staining, which defines ISEMF, has not been explored well
in ICC.
[3H]thymidine
incorporation into primary cultures of ISEMF indicates proliferative
responses to platelet-derived growth factor (PDGF)-BB, epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), insulin-like
growth factors I and II (IGF-I and IGF-II), interleukin-1 (IL-1
),
and tumor necrosis factor-
(TNF-
) (94). In this study, synergism
between PDGF-BB and IL-1
was demonstrated, and the proliferative
response was inhibited by elevation of cellular cAMP levels. The effect
of SCF was not reported. mRNA for
c-kit can be detected in 18Co cells,
human myofibroblasts cultured from a mucosal biopsy of human neonatal
colon (Mifflin, Saada, and Powell, unpublished
observations). The functional significance of this remains
to be determined. These cells also express SCF message and protein
(109), as well as message for PDGF-
receptor (Mifflin, Saada, and
Powell, unpublished observations). The growth factor(s) and receptor
set(s) crucial for the development or proliferation of ISEMF remain to
be more clearly determined.
![]() |
FUNCTIONS OF ISEMF |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mucosal Growth and Development
Intestinal mucosal development takes place along two broad perspectives (34, 72, 102, 186): 1) organogenesis (morphogenesis), during which interactions between the embryonic endoderm and the mesenchyme form the tubular foregut, midgut, and hindgut, which then differentiate into crypts and villi; and 2) cytodifferentiation of epithelial stem cells into the four major intestinal cell types (enterocytes, goblet cells, enteroendocrine cells, and Paneth cells). These are both complex processes that involve cell adhesion, proliferation, migration, differentiation, and, finally, apoptotic cell death (36, 73). There is mounting evidence that the intestinal myofibroblasts take part in both of these developmental events (33, 34, 53, 58, 65, 72, 74, 102, 155).Fibroblasts capable of driving either epithelial proliferation or
differentiation have been isolated from the gut lamina propria (58,
72). Over 15 years ago, Haffen et al. (72) showed that isolated
intestinal fibroblasts were as potent as dissected intestinal mesenchyme in inducing intestinal endoderm. More recently, they have
shown that the intestinal mucosa contains different clones of
"fibroblasts" that will drive either epithelial proliferation or
differentiation (58). Transforming growth factor-1 (TGF-
1) was
capable of transforming one set of isolated fibroblasts into
-SM-actin-expressing myofibroblasts and inhibiting their
proliferation. In contrast, proliferation of the second, typical,
fibroblast cell line was inhibited by IL-2 but not by TGF-
. When the
typical fibrocyte cell line was implanted into fetal endoderm, the
endoderm formed deep crypts due to proliferation of the epithelial
cells. In contrast, similar coculture containing the
-SM-actin-expressing myofibroblasts demonstrated differentiation
rather than proliferation of the epithelial cells: the endoderm
developed villi with mature differentiated enterocytes, goblet cells,
and endocrine cells (58). There were differences in the amount of
basement membrane proteins (laminin 1 and type IV collagen) produced by
the two (myo)fibroblast cells lines, but it is unclear whether matrix or growth factor secretion caused these different growth patterns.
Coculture of fibroblasts or myofibroblasts with epithelial cells will
cause the epithelial cell to proliferate and differentiate (33, 74).
Foreskin and lung fibroblasts (74) and primary cultured ISEMF (33) are
capable of inducing cellular differentiation of HT-29 and T84 human
colon cancer cells. When grown in collagen gels without
(myo)fibroblasts, T84 cells formed round, ball-shaped colonies. When
these (myo)fibroblasts were included, a basal lamina formed around the
T84 colonies, they differentiated into one-cell-layer hollow balls with
a lumen, and the epithelial cells changed from thin, cuboidal cells
with occasional microvilli to columnar enterocyte-like epithelial cells
with well-developed microvilli (74). In separate culture studies, it
was shown that hepatocyte growth factor (HGF) caused proliferation but
not differentiation of the T84 cells, whereas TGF- had the opposite
effect (74). Furthermore, antibodies against TGF-
or against the
TGF-
latency-associated protein abrogated the differentiating effect
of fibroblasts cocultured with the T84 cells (74). Thus
(myo)fibroblast-derived HGF appears to be a proliferative growth factor
for the intestinal epithelial stem cell, whereas
(myo)fibroblast-secreted TGF-
appears to promote epithelial cell differentiation.
The studies detailed above suggest that phenotypically different lamina
propria fibroblasts are capable of causing either proliferation or
differentiation of the intestinal epithelium, that basement membrane
formation is an important ingredient in differentiation, and, finally,
that HGF is a proliferating growth factor, whereas TGF- is a
differentiating growth factor for the intestinal epithelium.
Studies of keratinocyte growth factor (KGF) and KGF receptor
expression during fetal development suggest that this factor, also of
fibroblast origin, is equally important in mediating the morphogenic
mesenchymal-epithelial interactions (53).
A third axis of function and differentiation is a proximal-distal
gradient from duodenum to distal colon. Plateroti et al. (155) have
shown that myofibroblasts from proximal jejunum, distal ileum, and
proximal colon secrete different and characteristic amounts of HGF,
TGF-1, and epimorphin and have differing effects on endodermal
growth in coculture. These studies suggest that the ISEMF may be
important in proximal-distal gut differentiation as well as
crypt-villus morphogenesis (65).
There is evidence that myofibroblasts, like intestinal epithelial cells, proliferate, migrate, and differentiate along the crypt-villus axis. In [3H]thymidine pulse-labeling experiments of rabbit colon and adult mouse jejunum, both pericryptal myofibroblasts and crypt epithelial cells took up thymidine after a single pulse administration, i.e., both were proliferating (127, 148). Both the labeled cell populations appeared to migrate up the basement membrane over the course of 2-4 days, disappearing at the tip of the small intestine villi or the surface of the colon through the processes of exfoliation and/or apoptosis (73). These experiments suggest that myofibroblasts differentiate as they move from a discoid morphology at the base of the crypt to the stellate shape as they move toward the intestinal lumen. Perhaps maturation and differentiation of the myofibroblasts drive the maturation and differentiation of the epithelial cells that are moving pari passu up the basement membrane. It is also conceivable that there are signals from the epithelial cells that drive myofibroblast differentiation. It should be noted, however, that this finding of crypt myofibroblast labeling and migration could not be confirmed in studies with mouse small intestine and colon (142).
Protection and Wound Healing Functions of ISEMF
Contraction. ISEMF (95), as well as many other myofibroblasts, contain smooth muscle myosin isoforms in addition to smooth muscle actin. Thus they have the requisite machinery for contraction and/or motility. Histological studies of various intestinal disease states show that the small intestinal villus shortens dramatically after injury. This has been most clearly demonstrated with a highly reproducible model of intestinal epithelial injury in guinea pig ileum (133). This process is energy dependent and greatly facilitated by the presence of the enteric nervous system, i.e., villus shortening is significantly reduced if the tissue is depleted of ATP or if the tissue is functionally denervated by a neurotoxin such as TTX (133). Because the small intestine villus contains typical smooth muscle fibers, presumably originating from the muscularis mucosae, which emanate up through the core of the villus, it is possible that this villus shortening is due to contraction of these conventional smooth muscle elements. However, the extensive organization of the ISEMF network and its apparent innervation by the enteric nervous system make it a likely candidate as well (70, 205).It can be speculated also that the ISEMF network alone, or through its connections to the smooth muscle cells of the muscularis mucosae that extend up the villus core, is responsible for the rhythmic villus contractions observed in the small intestine (224). This phenomenon was first described over 150 years ago but has received little study in the past two decades. Almost certainly the ISEMF syncytium accounts for the mucosal contractions in the stomach, which lead to expulsion of gastric acid from the gastric pits in a jetlike fashion (79). Although these cells were described as "smooth muscle cells" originating from the muscularis mucosae, their anatomic location in the gastric mucosa suggests that they are the gastric counterpart of the ISEMF (194).
Intestinal myofibroblasts display receptors for contractile and relaxing agonists such as endothelin and atrial natriuretic peptide (59, 60, 205). Of interest, ISEMF fail to respond to other guanylate cyclase stimulants such as guanylin, heat-stable Escherichia coli enterotoxin (Sta), or sodium nitroprusside, suggesting that these receptors and/or the specific guanylate cyclases are absent from the ISEMF cells (205). The role of the ISEMF, which have the anatomic appearance of pericytes, in the autoregulation of lamina propria blood flow remains to be determined.
Restitution. The rapid migration of
epithelial cells over a denuded basement membrane is an important
intestinal repair response to minor/moderate injury (214). It is likely
that ISEMF play an important role in this process, both because their
location under the basement membrane is ideal for paracrine action and because myofibroblasts secrete the agents that thus far have been shown
to enhance epithelial cell migration in experimental disease states in
vivo and in wounding models in vitro. Factors promoting restitution
include PGE2 (in synergism with
prostacyclin) (13), IL-1 (37), interferon-
(IFN-
) (37),
TGF-
(37), EGF (37, 157, 170), acidic FGF (aFGF) and bFGF (39),
TGF-
(especially TGF-
3) (25, 130), and HGF (143, 195). The most
compelling evidence for a role of ISEMF in restitution comes from the
laboratories of Mahida and Podolsky (130). They have shown that the
active factor in conditioned media from primary cultures of ISEMF that promote IEC-6 or T84 epithelial cell motility is TGF-
3. The PGs may
have their action by virtue of stimulating HGF secretion, since
anti-HGF antibodies abrogate PG acceleration of gastric epithelial cell
restitution in a coculture model of gastric epithelial cells and
fibroblasts (195). Similarly, anti-TGF-
antibodies block the
restitution-promoting effects of IL-1
, IFN-
, TGF-
, EGF, aFGF,
and bFGF (37, 39). Thus these agents may not act directly on the
epithelial cell to promote cell motility; rather, they may augment the
secretion of and/or the expression of receptors for TGF-
and HGF. Of
interest, TGF-
may also enhance the barrier integrity of newly
formed tight junctions between epithelial cells and protect against the
barrier-destroying effects of IFN-
(154). Trefoil peptides also
stimulate intestinal epithelial restitution (106), but these factors
are secreted by epithelial mucus cells (goblet cells), not by ISEMF
(24). It is of interest that PDGF, an agent that stimulates
myofibroblast and smooth muscle motility, was without effect on the
motility (restitution property) of the intestinal epithelial cell (37).
Protection and repair. Tissue repair
is a complex, coordinated event [see part I of this review
(163)], in which there is release of various lipid mediators such
as eicosanoids, gases such as nitric oxide, cytokines such as TNF-,
IL-1, IL-6, IL-2, and IL-15, and the various growth factors mentioned
in the previous section. Many of these factors activate myofibroblasts,
resulting in myofibroblast motility and the release of ECM proteins and other growth factors. Remodeling of intestinal tissue (villous atrophy/crypt hyperplasia) is also an important response to gut injury
(121). There is evidence that myofibroblasts take part in this process
through the secretion of matrix metalloproteinases and other proteases
(32, 121), as well as secretion of TGF-
and KGF (5). In a cascade
fashion, growth factors induce angiogenesis and epithelial
proliferation and differentiation. The process is terminated by
myofibroblast apoptosis [see part I of this review (163)].
Myofibroblasts take part in the healing of gastrointestinal
ulcerations. Myofibroblasts are identified as -SM-actin-positive cells at the base of gastric and duodenal ulcers (140, 141) and in the
colon after experimental lesions (211). In vitro studies of primary
ISEMF cultures suggest that the important factors inducing myofibroblast activation and proliferation are TNF-
, IL-6, EGF, bFGF, IGF-I and IGF-II, PDGF-BB, and IL-1
(the latter two
synergistically) (94).
Many of the factors secreted by the activated myofibroblasts, as well
as their respective receptors, are upregulated in the intestine in
various disease states. Examples include PGs via cyclooxygenase (COX)-2
activity (104, 132, 196), TGF- (4, 38, 191), EGF (117), TGF-
(4,
38), bFGF (86), HGF (107, 180), and KGF (23, 54, 107) in experimental
colitis, small bowel injury (38), or gastric ulcer models or disease (86, 107, 180), and also in naturally occurring inflammatory bowel
disease (4). Furthermore, animals lacking TGF-
are more susceptible
to colonic injury, and this susceptibility is ameliorated by exogenous
administration of the factor (48). In fact, the exogenous
administration of many growth factors such as EGF (156, 170), bFGF
(87), IGF-I (152), KGF (230), and IL-II (118, 145) results in
amelioration of experimental or natural gastrointestinal injury.
Not only are these growth factors upregulated in intestinal disease or
injury, they have proliferative effects on normal or transformed
epithelial cell lines in culture and cause epithelial proliferation in
vivo. ET-1 (184), IL-2 (184), TGF- (96), IL-15 (167), aFGF (39),
bFGF (39), KGF (39, 107), and HGF (107) all have mitogenic activity in
epithelial cell culture models. Administration of EGF and TGF-
(81,
158), IGF-I and II (158), and KGF (82) to animals causes intestinal
epithelial cell and, in some cases, hepatocellular proliferation.
Transgenic animals overproducing IGF-I have predominantly muscle layer
proliferation (215), suggesting that this factor may be more important
in muscle repair.
A protective role for nitric oxide cannot be overlooked. Inducible nitric oxide synthase-deficient mice have poor wound healing that is corrected by exogenous administration of nitric oxide (226). Furthermore, administration of nitric oxide donors prevents gastrointestinal injury from nonsteroidal anti-inflammatory drugs (NSAIDs) (50). While other myofibroblasts (e.g., the renal mesangial cell) are significant producers of nitric oxide (112), it is unclear whether ISEMF or ICC are significant sources in the intestine (131, 225).
Fibrosis
Our understanding of fibrosis in the intestine is less advanced than in liver or skin, but intestinal smooth muscle cells and/or myofibroblasts have been incriminated in the process (see Ref. 66 for overview and original references). Fibrotic strictures of the small intestine, particularly the ileum, are often the outcome of repeated bouts of inflammation due to Crohn's disease (regional enteritis). Sections of Crohn's disease stricture show expansion of the muscularis mucosae from their usual three to five cell layers and accumulation of collagen around those cells. In addition, there is development of islands of smooth-muscle-like cells in the submucosa with invaginations of collagen septa into the circular and longitudinal muscle layers of the muscularis propria. Immunohistological studies and in situ hybridization studies show marked increases in type III collagen and RNA transcripts for procollagens I, III, and V (66). Gut bacterial flora may be important in this fibrosis; experimental injection of bowel flora into the bowel wall initiates intestinal TGF-A major question regarding intestinal fibrosis is whether the increase
in matrix production emanates from activated resident fibroblasts,
smooth muscle cells, or myofibroblasts. Normally, intestinal smooth
muscle expresses -SM actin, desmin, and tropomyosin. The "smooth
muscle cells" isolated and cultured from Crohn's disease bowel
demonstrate increased amounts of
-SM actin,
-enteric actin, and
desmin (66). In situ, normal ISEMF are desmin negative, but staining
characteristics can change during culture or disease states, and in
situ immunohistochemical studies of Crohn's disease strictures are not
available. We have found increased expression of desmin in ISEMF in
Crohn's disease intestine (West, unpublished observations). The intestinal "smooth-muscle-like"
cells responsible for intestinal fibrosis are more stellate in
appearance, have more prominent stress fibers, and contain more
extensive, dilated endoplasmic reticulum than conventional intestinal
smooth muscle cells (66), all characteristics of myofibroblasts
[see part I of this review (163)]. We believe, therefore,
that the cells responsible for fibrosis in Crohn's disease are
activated myofibroblasts (either ISEMF or ICC) and not conventional
intestinal smooth muscle. Furthermore, Western analysis demonstrates
that cultured ISEMF express several ECM proteins, including type IV
collagen and
1- and
1-laminin and fibronectin (122).
Perhaps this is semantics, because it is entirely possible that
myofibroblasts transdifferentiate from the smooth muscle cells of the
muscularis mucosae [see part I of this review (163)].
There are a number of interesting characteristics of the Crohn's
disease, collagen-producing, smooth-muscle-like cells. The mesenchymal
cells isolated from the lamina propria of Crohn's strictures produce
more total collagen and more type III collagen than mesenchymal cells
isolated from nonstrictured or normal intestine (66). TGF-
stimulates (67), while IL-1
and PDGF-BB downregulate, procollagen
secretion but not its synthesis (69). In contrast to the similar effect
of IL-1
and PDGF on collagen formation and secretion, IL-1 caused a
marked concentration-dependent increase in collagenase mRNA levels,
whereas PDGF had no effect (69). IL-1
and dexamethasone inhibit
collagen synthesis in dermal fibroblasts, yet they increase procollagen
synthesis by intestinal smooth muscle cells (128). At certain
concentrations in vitro, glucocorticoids actually increase procollagen
gene expression by human intestinal smooth muscle cells (68), a finding
with potentially important therapeutic implications for the treatment
of inflammatory bowel disease with corticosteroids.
Collagenous colitis is a disease that appears to be due to abnormalities of or activation of the subepithelial myofibroblasts of the colon (1, 231). This is a form of "inflammatory bowel disease," causing watery diarrhea predominantly in middle-aged or older women, who often have other manifestations of autoimmune diseases. The pathological abnormality in collagenous colitis is defined entirely at the microscopic level, where it is characterized by an expansion of the normal reticular band (collagen table) that exists in the subepithelial region of the surface epithelium of the colon, i.e., in the location of the ISEMF (231). Along with the collagen band, there is an increased number of the mononuclear inflammatory cells in the lamina propria. The possibility of an abnormality in collagen type or secretion in this disease has been previously studied with somewhat controversial findings (1). It has been suggested that in this disease there is a normal distribution of type IV collagen, increased type III collagen, and reduced or abnormal type I collagen production (1). Normal type IV collagen distribution in this disease indicates that the band is not an expanded basement membrane. More recent studies suggest increases in type VI collagen and tenascin in the collagen band under the surface epithelium, with focal increases in types I, III, and VI collagen in the area of the crypts (1). However, no increase in type VI collagen mRNA was found in the myofibroblasts around and entrapped in the collagen table. These studies suggest that the accumulation of type VI collagen is not caused by increased collagen synthesis by the myofibroblasts but rather by abnormalities in the degradation of the intracellular matrix, e.g., decreased secretion of metalloproteinases or increased secretion of tissue inhibitors of metalloproteinases (1).
Granulomas of the intestine are basically of two types: accumulations
of only macrophages as seen often in Crohn's disease or
-SM-actin-positive myofibroblasts surrounding macrophages and/or
giant cells, which are thought to be of either macrophage or
myofibroblast origin, as commonly seen in sarcoidosis or foreign body
reactions (174). A model for granuloma formulation in the intestine is
the injection of sterile bacterial peptidoglycan-polysaccharide polymers into the bowel wall (232). The bacterial cell wall polymers increased both TGF-
immunostaining and collagen deposition, as well
as collagen
-1 mRNA in the granulomas (211). Furthermore, TGF-
directly stimulated collagen type I, TGF-
1, IL-1
, and IL-6 mRNA
in myofibroblasts cultured from the granulomas (211). Thus granuloma
myofibroblasts represent another potential origin for the intestinal
fibrosis of Crohn's disease.
Immunology and Inflammation
Immune cell functions, such as secretion of cytokines and expression of adhesion proteins by epithelial cells and other nontraditional immune cells, have recently been a topic of much investigation (56). Cytokines produced by ISEMF (20, 56, 147, 171, 193) in response to stimulation by inflammatory cytokines such as IL-1 and/or TNF-At the electron microscopic level, it is possible to find close apposition of ISEMF and lymphocytes, suggesting that the myofibroblasts may take part in the growth and development of the T cell (202). Fiocchi (56), Toyoda et al. (202), and Roberts et al. (171) have shown that experimentally induced proliferative responses in T cells are enhanced by coculture with intestinal fibroblasts or with smooth muscle cells.
PGs derived from either constitutive (COX-1) or inducible (COX-2) forms of cyclooxygenase (PGH2 synthase) have fundamental regulatory roles in gastrointestinal barrier function, inflammation, the immunophysiology of intestinal electrolyte transport and motility, and gastrointestinal neoplasia (13, 21, 26, 42, 46, 159, 210). The cellular sources of PG in normal and diseased intestine are poorly defined. It does seem likely, however, that the epithelium is the least contributor. When the intestinal mucosa is separated with a combination of sharp dissection and Ca2+ chelation into epithelial and subepithelial (lamina propria, submucosa, and muscularis propria) fractions, 95-99% of rat mucosal PG synthesis emanates from the subepithelial fractions (27, 28, 114). Myofibroblasts are but one of several tissue elements in the subepithelium capable of producing PGs (11, 77, 104, 122, 197, 205); white blood cells of various types, smooth muscle cells, endothelial cells, and conventional fibroblasts are among the other PG-producing constituents (159). The relative proportions of PGs secreted in normal or inflamed states by intestinal myofibroblasts compared with these other elements remain to be determined. Studies of nonstimulated intestine show COX-1 to be the predominant isoform producing basal secretion of PGs in the gastrointestinal tract (98). In the experiments noted above, in which intestine was dissected into epithelial and subepithelial fractions, it is likely that COX-2 is activated by the trauma of the experimental procedures.
Immunohistochemical studies show constitutive expression of COX-1 in the crypt epithelium of the small intestine (26) and predominantly in mucous neck cells of the gastric glands (88). However, epithelial COX-2 expression can be induced. Experimental injury (injection of endotoxin) (52) and bacterial (Salmonella) invasion (47), as well as natural disease states such as Crohn's colitis, ulcerative colitis (76, 187), and colonic adenocarcinoma (45), result in expression of COX-2 in intestinal epithelial cells. Furthermore, COX-2 has been cloned from nontransformed rat intestinal epithelial (RIE-1) cells, a cryptlike intestinal epithelial cell line (43).
ISEMF also express COX-1 and COX-2 (Fig. 3)
(77, 104, 122, 205). IL-1 increased COX-1 mRNA in 18Co ISEMF after
24 h exposure, but the threefold increase in message was not
accompanied by detectable increases in protein, as determined by
Western analysis (175). In contrast, IL-1
induces an exponential
increase in COX-2 mRNA and protein levels in 18Co cells. Under these
conditions, COX-2 accounts for 95% of the total
PGE2 synthesis (77).
|
Immunocytochemical studies localize COX-2 to the lamina propria of the inflamed stomach and intestine (52, 168, 187). This subepithelial localization of COX-2 is usually ascribed to either macrophages or blood vessels, and expression in ISEMF has not been sought or clearly demonstrated. In contrast, COX-2 expression has been definitively located to lamina propria interstitial mesenchymal cells (probably ISEMF) in the early stages of polyp formation in the adenomatous polyposis coli (APC) knockout mouse (146). Thus the relative roles of epithelial, white blood cell, endothelial, and ISEMF PG production, as well as the relative roles of COX-1 vs. COX-2 enzymatic PG production, in intestinal barrier function, inflammation, immunophysiology, and neoplasia remain to be determined. Most studies suggest COX-1 is the predominant enzyme responsible for barrier function and protection against damage, whereas COX-2 expression is increased in gastrointestinal inflammation (13, 26, 29, 46, 47, 52, 210, 212). Whether COX-2 inhibition is sufficient to alleviate pain and inflammation is still a topic of debate (168, 213). Nevertheless, this concept of differential functions of COX-1 and COX-2 has been the theoretical basis for the development of COX-2-selective NSAIDs (210). This concept has been challenged by experiments that show that COX-1 contributes to the inflammatory responses of the gastrointestinal mucosa and that inhibition of COX-2 can exacerbate inflammation in the colon (168, 213). To date, initial reports suggest that selective COX-2 inhibition does, indeed, cause less gastrointestinal mucosal damage than conventional NSAIDs and is effective in symptom relief (75, 120, 185).
Water and Electrolyte Transport
Secretion. The close proximity of ISEMF to intestinal epithelial cells, being separated only by the basement membrane, makes it reasonable to propose that these cells might be paracrine regulators of intestinal electrolyte transport. To test this hypothesis, we cocultured or separately cultured and then acutely juxtaposed piglet small intestine (P2JF) myofibroblasts or human colonic (18Co) myofibroblasts with T84 cells, a human colon carcinoma cell line that maintains the ability to secrete Cl
|
|
The studies above were performed in a reductionist model: cell culture
of epithelium and myofibroblasts. There is, however, evidence from
studies of native tissues that PG release is part of immune mediator,
neurotransmitter, and cholera toxin-induced Cl secretion (7, 21, 93,
103, 123, 153, 159, 162, 189, 219). These studies also raise the
question whether some of the abnormal electrolyte secretory responses
in the intestine of
W/Wv mice are due
to loss of ISEMF rather than loss of mast cells (216). Some of these
abnormal electrolyte transport responses (e.g., the cholera toxin
response) were not reconstituted by bone marrow
transplantation that replaced mast cells in these
c-kit-negative animals (216).
Absorption. Recently, Naftalin and colleagues (137, 138) have published intriguing experiments that suggest ISEMF also have a critical function in intestinal water and electrolyte absorption. These investigators had previously suggested that colonic crypts act as suction devices to dehydrate feces in the distal segment of the mammalian colon (150, 160). Such a process requires that the colon absorb fluid hypertonically (which it is known to do) (12), but the mechanism of hypertonic absorption by an epithelium has heretofore not been evident (161). Naftalin and colleagues showed that the ISEMF sheath represents a diffusion barrier to Na+ transport that creates a significantly hypertonic middle compartment between the epithelial tight junctions and vascular system. It has been shown experimentally that such a three-compartment model will permit hypertonic transport in keeping with the Curran-MacIntosh model of water movement across epithelial tissues (30, 137, 138). Furthermore, they demonstrated proliferation of the ISEMF sheath in response to dietary Na+ depletion, which would account for the increase in Na+ and water absorption in high ANG II-high aldosterone states. ANG II (and/or aldosterone) has been demonstrated to cause proliferation of cardiac myofibroblasts and to increase their secretion of ECM fibrils (19).
ISEMF may be responsible for differentiation of epithelial cells from a secretory to an absorptive phenotype. When T84 colon cells, a secretory cell line, are cocultured with 18Co human myofibroblasts, fluid-filled domes develop under the T84 cells (205). Dome formation in epithelial cell culture systems is usually thought to result from Na+ and water transport from the culture media to the space between the epithelium and the plastic culture dish.
Intestinal Polyps and Neoplasia
There is a growing body of evidence for a role of myofibroblasts in the pathogenesis of intestinal inflammatory (hyperplastic) polyps, stromal tumors, hamartomatous tumors, adenomas, and colon cancer. 1) Myofibroblasts themselves can undergo neoplastic transformation (78, 105, 139, 188). The resulting mesenchymal tumors likely constitute a significant proportion of the neoplasms previously called leiomyomas, leiomyosarcomas, fibrosarcomas, histiocytomas, spindle cell tumors, and desmoid tumors. These tumors are now often lumped under a single encompassing term of gastrointestinal stromal tumors (GISTs). 2) Myofibroblasts are the primary mesenchymal element in hyperplastic and adenomatous polyps (Fig. 6) (108, 113, 178, 181). 3) Myofibroblasts appear to be the primary mesenchymal element in the hamartomatous polyps seen in juvenile polyposis coli (83, 91) and in Peutz-Jeghers syndrome (108) and perhaps account for the mesenchymal elements in the hamartomatous inflammatory polyps seen in chronic ulcerative colitis (192). 4) Myofibroblasts are responsible for the desmoplastic (fibrotic) reactions seen in many tumors of the gastrointestinal tract, e.g., carcinoid tumors (198, 228). 5) They play a key role in the growth of intestinal neoplasms and in the promotion and/or prevention of metastases (15, 17, 51, 129, 150, 165, 166). 6) Myofibroblasts are a prominent subepithelial element in familial adenomatous polyposis (FAP), and they may well play a key role in many of the extraintestinal manifestations of the FAP variant known as Gardner's syndrome (62, 149). 7) It is unclear if it is the ISEMF (146) or the epithelial cell itself (179, 182, 203) that is the key to NSAID-induced regression of colonic polyps and NSAID prevention of the development (chemoprevention) of colonic adenocarcinoma.
|
GISTs are the most common of the mesenchymal tumors of the gastrointestinal tract. Recently, it has been shown that they make up a very high percentage of conventional mesenchymal tumors and can be differentiated from classic smooth muscle tumors (leiomyomas) by the expression of c-kit (78, 105, 139, 188). These c-kit-expression cells are also CD34+, suggesting a stem cell origin and, furthermore, that they originate from ICC. Because ISEMF may well be c-kit-positive cells as well, it remains to be determined which myofibroblast is the cell of origin. Alternatively, GISTs may be derived from some progenitor stem cell of both intestinal myofibroblasts. GISTs often contain mutations in the transmembrane or tyrosine kinase domain of c-kit. The stable introduction of a mutant c-kit cDNA into murine lymphoid cells induces malignant transformation. This suggests that these mutations contribute to tumor formation and, as such, are "gain of function" mutations.
Myofibroblasts appear to be the primary mesenchymal element in the lamina propria of sporadic, hyperplastic, hamartomatous, and adenomatous polyps (108, 113, 178, 181). They are also the principal mesenchymal cell of inherited neoplasms such as juvenile polyposis, Peutz-Jeghers syndrome, and familial polyposis (91, 108, 113). This has led Kinzler and Vogelstein (108) to classify juvenile polyps and the hamartomas of ulcerative colitis as members of the "landscaper defect tumors." The hypothesis is that the stromal cells secrete growth factors that make the epithelium more susceptible to neoplastic transformation, much in the same way cultivated soil allows for the better growth of plants (108). Primary defects in the mesenchymal cells of juvenile polyposis tumors are loss of a suppressor locus in chromosome 10q22 (91) or germ line mutations of the gene SMAD4 located on chromosome 18q21 (83). Hyperplastic polyps are characterized by abnormally shaped or branched crypts (3). It is intriguing to speculate that myofibroblasts, also through secretion of growth factors, might induce this abnormal crypt morphology.
Pericryptal fibroblasts are believed to play a role in the histological
features and tumor growth patterns of colorectal neoplasms (169, 227).
For example, it has been suggested that well-developed ISEMF are a more
consistent feature of adenomas than of carcinomas, and polypoid
carcinomas are more likely to have well-developed ISEMF than
nonpolypoid growths (227). ISEMF appear to be responsible for the
desmoplastic (fibrotic) reactions seen in many gastrointestinal tumors
(198, 228). Because TGF- is a prominent fibrogenic growth factor, a
role for this cytokine has been suggested (116). The TGF-
could be
of either myofibroblast or neoplastic epithelial origin. Furthermore,
ISEMF have been proposed to play an important role in tumor metastasis,
either through formation of an abnormal basement membrane (15, 129,
165, 166), through their ability to secrete matrix metalloproteinases
that allow the breakdown of tumor-containing connective tissue (17,
51), or through their ability to alter cell-to-cell adhesion protein
expression (40). Because myofibroblasts themselves are mobile cells,
they could conceivably "carry" tumor cells into adjacent tissue,
lymphatics, or blood vessels (129). Perhaps most importantly, TGF-
secreted by tumor myofibroblasts may directly stimulate tumor cell
motility (37, 39, 130).
In addition to its potential to cause desmoplastic reactions in cancer,
TGF- has important effects on tumor cell growth. Because TGF-
induces apoptotic cell death in many epithelial cells, the finding that
the type II receptor (TGF-
RII) is mutated or absent in many colon
carcinomas suggests that such mutations might play a fundamental role
in tumor development (125, 126). These mutations in TGF-
RII develop
predominantly from microsatellite instability secondary to the DNA
mismatch gene repair abnormalities seen in hereditary nonpolyposis
colon cancer syndrome (2) and in ulcerative colitis-associated
colorectal neoplasms (192) but not necessarily in sporadic colorectal
cancer (204). Patients with colorectal cancer may have increased plasma
levels of TGF-
, and this appears to be of lamina propria
(myofibroblast?) origin (204). Because TGF-
production and receptors
may be of either myofibroblast or epithelial origin, more definition of
this area is needed to sort out the role of this growth hormone and its receptors in colorectal cancer.
Perhaps the most important connection between myofibroblasts and colorectal cancer is in the definition of the mechanisms whereby NSAIDs cause regression of polyps in FAP and the mechanism of NSAID chemoprevention of sporadic colon cancer. Aspirin and other NSAIDs clearly are chemopreventive for the development of polyp expression in mouse and human FAP (6, 62, 146, 149) and in sporadic colorectal cancer in humans (63, 64, 177). The mechanism of this antitumorigenic and chemopreventive effect is unclear and much discussed (41, 49, 71, 80, 124, 134, 183, 221, 223). The most recent hypothesis is that NSAIDs cause increased apoptosis of colonic epithelial cells (179, 182, 203) through inhibition of PG synthesis; the resulting elevated arachidonic acid levels in the cell are thought to stimulate the conversion of sphingomyelin to ceramide, a known inducer of apoptosis (22). An alternative hypothesis is that NSAIDs may cause apoptosis of growth-factor-secreting ISEMF, which leads secondarily to decreased epithelial proliferation or increased epithelial apoptosis.
COX-1 is detected in normal colonic epithelial cells (26) as well as colonic cancers (45, 99). In contrast, COX-2 is rarely detectable in normal tissues but is found in >90% of colon tumors. COX-2 expression is present in less than one-half of premalignant colonic polyps (45, 99). COX-1 and COX-2 are also found in ISEMF (77, 122). Therefore, the key question is whether the effect of NSAIDs resides at the level of the neoplastic epithelial cell (223) or in the subepithelial mesenchymal tissue (probably myofibroblasts) (71, 80). Of note, NSAID administration causes apoptosis of embryonic fibroblasts (119). Loss of growth-factor-producing ISEMF, through a similar apoptotic process, could affect tumor epithelial cell proliferation. Studies of the APC model give some insight into this question (164). In the APC knockout mouse, specific COX-2 inhibitors have been shown to suppress the development of intestinal polyps (146), and the site of COX-2 expression in these animals was subepithelial mesenchymal cells, probably myofibroblasts (146). However, adenomas originating in Min mice also express high levels of COX-2, some of which can be localized to the epithelium (222). These observations, combined with the fact that a large percentage of epithelial tumors express COX-2, suggest that, along the progression from polyp to cancer, acquisition of the ability to express COX-2 provides a selective advantage to the cancer cell.
A final area of consideration is the possible role of tissue myofibroblasts in the desmoid tumors, cutaneous cysts, dental abnormalities, osteomas, and retinal pigment epithelial abnormalities often seen in the Gardner's variant of FAP (190). The desmoid tumors are certainly of myofibroblast origin, and myofibroblasts are located in the areas of the other various extraintestinal manifestations [see part I of this review (163)]. A mouse model with these extraintestinal manifestations has been reported (190), and perhaps study of this animal will clarify the role of the myofibroblasts in this syndrome.
![]() |
CONCLUSIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Scientists are just beginning to appreciate the multiple roles of intestinal myofibroblasts, cells that were discovered nearly half a century ago. They play fundamental roles in the growth and development of the intestine, its protection from noxious agents, and its repair after damage. These cells have specific functions in the gastrointestinal tract, including the neuromodulation of intestinal motility and the regulation of intestinal water and electrolyte transport. They also play fundamental roles in intestinal inflammation, but specific functions such as altering the phenotype of lymphocytes and/or the development of oral tolerance remain to be determined. Their exact role in the development of intestinal neoplasms is still unclear, but some effect seems certain. These cells will be exciting targets of investigation over the next several years.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Terri Kirschner for excellent editorial expertise.
![]() |
FOOTNOTES |
---|
We acknowledge the support of National Institute of Diabetes and Digestive and Kidney Diseases Grant 2R7 DK-15350, a grant from the Crohn's and Colitis Foundation of America, and support from The Keating Fund for Research Prevention of Cancer, administered by the University of Texas Medical Branch (UTMB) Small Grants Program, UTMB at Galveston, TX.
Address for reprint requests and other correspondence: D. W. Powell, Dept. of Internal Medicine, Univ. of Texas Medical Branch at Galveston, 4.108 John Sealy Annex, 0567, 301 Univ. Blvd., Galveston, TX 77555-0567 (E-mail: dpowell{at}utmb.edu).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Aigner, T.,
D. Neureiter,
S. Muller,
G. Kuspert,
J. Belke,
and
T. Kirchner.
Extracellular matrix composition and gene expression in collagenous colitis.
Gastroenterology
113:
136-143,
1997[Medline].
2.
Akiyama, Y.,
R. Iwanaga,
K. Saitoh,
K. Shiba,
K. Ushio,
E. Ikeda,
T. Iwama,
T. Nomizu,
and
Y. Yuasa.
Transforming growth factor type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Gastroenterology
112:
33-39,
1997[Medline].
3.
Araki, K.,
T. Ogata,
M. Kobayashi,
and
R. Yatani.
A morphological study on the histogenesis of human colorectal hyperplastic polyps.
Gastroenterology
109:
1468-1474,
1995[Medline].
4.
Babyatsky, M. W.,
G. Rossiter,
and
D. K. Podolsky.
Expression of transforming growth factors and
in colonic mucosa in inflammatory bowel disease.
Gastroenterology
110:
975-984,
1996[Medline].
5.
Bajaj-Elliott, M.,
R. Poulsom,
S. L. Pender,
N. C. Wathen,
and
T. T. MacDonald.
Interactions between stromal cell-derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia.
J. Clin. Invest.
102:
1473-1480,
1998
6.
Barnes, C. J.,
and
M. Lee.
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.
Gastroenterology
114:
873-877,
1998[Medline].
7.
Barrett, K. E.
Positive and negative regulation of chloride secretion in T84 cells.
Am. J. Physiol.
265 (Cell Physiol. 34):
C859-C868,
1993
8.
Bauer, I.,
G. A. Wanner,
H. Rensing,
C. Alte,
E. A. Miescher,
B. Wolf,
B. H. Pannen,
M. G. Clemens,
and
M. Bauer.
Expression pattern of heme oxygenase isoenzymes 1 and 2 in normal and stress-exposed rat liver.
Hepatology
27:
829-838,
1998[Medline].
9.
Beltinger, J.,
S. Makh,
W. A. Stack,
C. J. Hawkey,
and
Y. R. Mahida.
Adult human colonic subepithelial myofibroblasts (HCSM) regulate epithelial secretory response and barrier function via distinct pathways (Abstract).
Gastroenterology
114:
A1128,
1998.
10.
Bernex, F.,
P. De Sepulveda,
C. Kress,
C. Elbaz,
C. Delouis,
and
J. J. Panthier.
Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and WlacZ/WlacZ mouse embryos.
Development
122:
3023-3033,
1996
11.
Berschneider, H. M.,
and
D. W. Powell.
Fibroblasts modulate intestinal secretory responses to inflammatory mediators.
J. Clin. Invest.
89:
484-489,
1992[Medline].
12.
Bleakman, D.,
and
R. J. Naftalin.
Hypertonic fluid absorption from rabbit descending colon in vitro.
Am. J. Physiol.
258 (Gastrointest. Liver Physiol. 21):
G377-G390,
1990
13.
Blikslager, A. T.,
M. C. Roberts,
J. M. Rhoads,
and
R. A. Argenzio.
Prostaglandins I2 and E2 have a synergistic role in rescuing epithelial barrier function in porcine ileum.
J. Clin. Invest.
100:
1928-1933,
1997
14.
Bockman, D. E.,
and
G. S. Sohal.
A new source of cells contributing to the developing gastrointestinal tract demonstrated in chick embryos.
Gastroenterology
114:
878-882,
1998[Medline].
15.
Bouziges, F.,
P. Simo,
P. Simon-Assmann,
K. Haffen,
and
M. Kedinger.
Altered deposition of basement-membrane molecules in co-cultures of colonic cancer cells and fibroblasts.
Int. J. Cancer
48:
101-108,
1991[Medline].
16.
Brannan, C. I.,
S. D. Lyman,
D. E. Williams,
J. Eisenman,
D. M. Anderson,
D. Cosman,
M. A. Bedell,
N. A. Jenkins,
and
N. G. Copeland.
Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains.
Proc. Natl. Acad. Sci. USA
88:
4671-4674,
1991[Abstract].
17.
Brown, P. D.
Matrix metalloproteinases in gastrointestinal cancer.
Gut
43:
161-163,
1998
18.
Campbell, F.,
B. Hewlett,
J. Ho,
J. Huizinga,
and
R. H. Riddell.
Interstitial cells of Cajal (ICC) are absent or deranged in intestinal pseudo-obstruction (Abstract).
Lab. Invest.
78:
61A,
1998.
19.
Campbell, S. E.,
J. S. Janicki,
and
K. T. Weber.
Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone.
J. Mol. Cell. Cardiol.
27:
1545-1560,
1995[Medline].
20.
Casola, A.,
A. Kapoor,
J. I. Saada,
R. Mifflin,
D. W. Powell,
and
S. E. Crowe.
Chemokine expression by intestinal myofibroblasts (Abstract).
Gastroenterology
112:
A944,
1997.
21.
Castro, G. A.,
and
D. W. Powell.
The physiology of the mucosal immune system and immune-mediated responses in the gastrointestinal tract.
In: Physiology of the Gastrointestinal Tract, edited by L. R. Johnson. New York: Raven, 1994, p. 709-750.
22.
Chan, T. A.,
P. J. Morin,
B. Vogelstein,
and
K. W. Kinzler.
Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis.
Proc. Natl. Acad. Sci. USA
95:
681-686,
1998
23.
Chedid, M.,
J. S. Rubin,
K. G. Csaky,
and
S. A. Aaronson.
Regulation of keratinocyte growth factor gene expression by interleukin 1.
J. Biol. Chem.
269:
10753-10757,
1994
24.
Chinery, R.,
and
R. J. Coffey.
Trefoil peptides: less clandestine in the intestine.
Science
274:
204,
1996[Medline].
25.
Ciacci, C.,
S. E. Lind,
and
D. K. Podolsky.
Transforming growth factor regulation of migration in wounded rat intestinal epithelial monolayers.
Gastroenterology
105:
93-101,
1993[Medline].
26.
Cohn, S. M.,
S. Schloemann,
T. Tessner,
K. Seibert,
and
W. F. Stenson.
Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1.
J. Clin. Invest.
99:
1367-1379,
1997
27.
Craven, P. A.,
and
F. R. DeRubertis.
Patterns of prostaglandin synthesis and degradation in isolated superficial and proliferative colonic epithelial cells compared to residual colon.
Prostaglandins
26:
583-604,
1983[Medline].
28.
Craven, P. A.,
and
F. R. DeRubertis.
Profiles of eicosanoid production by superficial and proliferative colonic epithelial cells and sub-epithelial colonic tissue.
Prostaglandins
32:
387-399,
1986[Medline].
29.
Cryer, B.,
and
M. Feldman.
Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.
Am. J. Med.
104:
413-421,
1998[Medline].
30.
Curran, P. F.,
and
J. R. MacIntosh.
A model system for biological water transport.
Nature
193:
347-348,
1962.
31.
Daniel, E. E.,
Y. F. Wang,
and
F. S. Cayabyab.
Role of gap junctions in structural arrangements of interstitial cells of Cajal and canine ileal smooth muscle.
Am. J. Physiol.
274 (Gastrointest. Liver Physiol. 37):
G1125-G1141,
1998
32.
Daum, S.,
U. Bauer,
H. D. Foss,
D. Schuppan,
H. Stein,
E. O. Riecken,
and
R. Ullrich.
Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease.
Gut
44:
17-25,
1999
33.
Del Buono, R.,
J. Beltinger,
L. Jackson,
C. J. Hawkey,
and
Y. R. Mahida.
Primary adult human colonic subepithelial myofibroblasts induce morphological and cytological differentiation in T84 colonic epithelial cells (Abstract).
Gastroenterology
114:
A584,
1998.
34.
Del Buono, R.,
K. A. Fleming,
A. L. Morey,
P. A. Hall,
and
N. A. Wright.
A nude mouse xenograft model of fetal intestine development and differentiation.
Development
114:
67-73,
1992[Abstract].
35.
Desaki, J.,
T. Fujiwara,
and
T. Komuro.
A cellular reticulum of fibroblast-like cells in the rat intestine: scanning and transmission electron microscopy.
Arch. Histol. Jpn.
47:
179-186,
1984[Medline].
36.
Dieckgraefe, B. K.,
S. A. Santoro,
and
D. H. Alpers.
Immunolocalization of -integrin subunits and extracellular matrix components during human colonic organogenesis.
Gastroenterology
110:
58-71,
1996[Medline].
37.
Dignass, A. U.,
and
D. K. Podolsky.
Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor .
Gastroenterology
105:
1323-1332,
1993[Medline].
38.
Dignass, A. U.,
J. L. Stow,
and
M. W. Babyatsky.
Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor and
.
Gut
38:
687-693,
1996[Abstract].
39.
Dignass, A. U.,
S. Tsunekawa,
and
D. K. Podolsky.
Fibroblast growth factors modulate intestinal epithelial cell growth and migration.
Gastroenterology
106:
1254-1262,
1994[Medline].
40.
Dimanche-Boitrel, M. T.,
L. Vakaet, Jr.,
P. Pujuguet,
B. Chauffert,
M. S. Martin,
A. Hammann,
F. Van Roy,
M. Mareel,
and
F. Martin.
In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts.
Int. J. Cancer
56:
512-521,
1994[Medline].
41.
DuBois, R. N.
Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas.
Gastroenterology
108:
1310-1314,
1995[Medline].
42.
DuBois, R. N.,
S. B. Abramson,
L. Crofford,
R. A. Gupta,
L. S. Simon,
L. B. Van De Putte,
and
P. E. Lipsky.
Cyclooxygenase in biology and disease.
FASEB J.
12:
1063-1073,
1998
43.
DuBois, R. N.,
M. Tsujii,
P. Bishop,
J. A. Awad,
K. Makita,
and
A. Lanahan.
Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells.
Am. J. Physiol.
266 (Gastrointest. Liver Physiol. 29):
G822-G827,
1994
44.
Dy, E.,
D. W. Powell,
J. Valentich,
P. B. Ernst,
M. Oda,
and
S. E. Crowe.
Neutrophil-mesenchymal interactions and the regulation of intestinal epithelial ion secretion (Abstract).
Gastroenterology
108:
A282,
1995.
45.
Eberhart, C. E.,
R. J. Coffey,
A. Radhika,
F. M. Giardiello,
S. Ferrenbach,
and
R. N. DuBois.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Gastroenterology
107:
1183-1188,
1994[Medline].
46.
Eberhart, C. E.,
and
R. N. DuBois.
Eicosanoids and the gastrointestinal tract.
Gastroenterology
109:
285-301,
1995[Medline].
47.
Eckmann, L.,
W. F. Stenson,
T. C. Savidge,
D. C. Lowe,
K. E. Barrett,
J. Fierer,
J. R. Smith,
and
M. F. Kagnoff.
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and F2 production.
J. Clin. Invest.
100:
296-309,
1997
48.
Egger, B.,
F. Procaccino,
J. Lakshmanan,
M. Reinshagen,
P. Hoffmann,
A. Patel,
W. Reuben,
S. Gnanakkan,
L. Liu,
L. Barajas,
and
V. E. Eysselein.
Mice lacking transforming growth factor have an increased susceptibility to dextran sulfate-induced colitis.
Gastroenterology
113:
825-832,
1997[Medline].
49.
Elder, D. J.,
and
C. Paraskeva.
NSAIDs to prevent colorectal cancer: a question of sensitivity.
Gastroenterology
113:
1999-2003,
1997[Medline].
50.
Elliott, S. N.,
W. McKnight,
G. Cirino,
and
J. L. Wallace.
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats.
Gastroenterology
109:
524-530,
1995[Medline].
51.
Fabra, A.,
M. Nakajima,
C. D. Bucana,
and
I. J. Fidler.
Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice.
Differentiation
52:
101-110,
1992[Medline].
52.
Ferraz, J. G.,
K. A. Sharkey,
B. K. Reuter,
S. Asfaha,
A. W. Tigley,
M. L. Brown,
W. McKnight,
and
J. L. Wallace.
Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage.
Gastroenterology
113:
195-204,
1997[Medline].
53.
Finch, P. W.,
G. R. Cunha,
J. S. Rubin,
J. Wong,
and
D. Ron.
Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions.
Dev. Dyn.
203:
223-240,
1995[Medline].
54.
Finch, P. W.,
V. Pricolo,
A. Wu,
and
S. D. Finkelstein.
Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease.
Gastroenterology
110:
441-451,
1996[Medline].
55.
Finotto, S.,
Y. A. Mekori,
and
D. D. Metcalfe.
Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems.
J. Clin. Invest.
99:
1721-1728,
1997
56.
Fiocchi, C.
Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions.
Am. J. Physiol.
273 (Gastrointest. Liver Physiol. 36):
G769-G775,
1997
57.
Forstermann, U.,
J. P. Boissel,
and
H. Kleinert.
Expressional control of the "constitutive" isoforms of nitric oxide synthase (NOS I and NOS III).
FASEB J.
12:
773-790,
1998
58.
Fritsch, C.,
P. Simon-Assmann,
M. Kedinger,
and
G. S. Evans.
Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine.
Gastroenterology
112:
826-838,
1997[Medline].
59.
Furuya, K.,
S. Furuya,
and
S. Yamagishi.
Intracellular calcium responses and shape conversions induced by endothelin in cultured subepithelial fibroblasts of rat duodenal villi.
Pflügers Arch.
428:
97-104,
1994[Medline].
60.
Furuya, S.,
and
K. Furuya.
Characteristics of cultured subepithelial fibroblasts of rat duodenal villi.
Anat. Embryol.
187:
529-538,
1993[Medline].
61.
Furuya, S.,
R. Nagata,
Y. Ozaki,
K. Furuya,
T. Nakayama,
and
M. Nagahama.
A monoclonal antibody to astrocytes, subepithelial fibroblasts of small intestinal villi and interstitial cells of the myenteric plexus layer.
Anat. Embryol.
195:
113-126,
1997[Medline].
61a.
Gannon, B. J.,
and
M. A. Perry.
Histoanatomy and ultrastructure of vasculature of alimentary tract.
In: Handbook of Physiology. The Gastrointestinal System. Motility and Circulation. Bethesda, MD: Am. Physiol. Soc., 1989, sect. 6, vol. I, chapt. 36, p. 1301-1334.
62.
Giardiello, F. M.,
S. R. Hamilton,
A. J. Krush,
S. Piantadosi,
L. M. Hylind,
P. Celano,
S. V. Booker,
C. R. Robinson,
and
G. J. Offerhaus.
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
N. Engl. J. Med.
328:
1313-1316,
1993
63.
Giovannucci, E.,
K. M. Egan,
D. J. Hunter,
M. J. Stampfer,
G. A. Colditz,
W. C. Willett,
and
F. E. Speizer.
Aspirin and the risk of colorectal cancer in women.
N. Engl. J. Med.
333:
609-614,
1995
64.
Giovannucci, E.,
E. B. Rimm,
M. J. Stampfer,
G. A. Colditz,
A. Ascherio,
and
W. C. Willett.
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
Ann. Intern. Med.
121:
241-246,
1994
65.
Goyal, A.,
R. Singh,
E. A. Swietlicki,
M. S. Levin,
and
D. C. Rubin.
Characterization of rat epimorphin/syntaxin 2 expression suggests a role in crypt-villus morphogenesis.
Am. J. Physiol.
275 (Gastrointest. Liver Physiol. 38):
G114-G124,
1998
66.
Graham, M. F.
Pathogenesis of intestinal strictures in Crohn's diseasean update.
Inflamm. Bowel. Dis.
1:
220-227,
1995.
67.
Graham, M. F.,
G. R. Bryson,
and
R. F. Diegelmann.
Transforming growth factor 1 selectively augments collagen synthesis by human intestinal smooth muscle cells.
Gastroenterology
99:
447-453,
1990[Medline].
68.
Graham, M. F.,
A. Willey,
J. Adams,
and
R. F. Diegelmann.
Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells.
Gastroenterology
109:
1454-1461,
1995[Medline].
69.
Graham, M. F.,
A. Willey,
J. Adams,
D. Yager,
and
R. F. Diegelmann.
Interleukin 1 down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells.
Gastroenterology
110:
344-350,
1996[Medline].
70.
Guldner, F. H.,
J. R. Wolff,
and
D. G. Keyserlingk.
Fibroblasts as a part of the contractile system in duodenal villi of rat.
Z. Zellforsch. Mikrosk. Anat.
135:
349-360,
1972[Medline].
71.
Gupta, R. A.,
and
R. N. DuBois.
Aspirin, NSAIDS, and colon cancer prevention: mechanisms?
Gastroenterology
114:
1095-1098,
1998[Medline].
72.
Haffen, K.,
B. Lacroix,
M. Kedinger,
and
P. M. Simon-Assmann.
Inductive properties of fibroblastic cell cultures derived from rat intestinal mucosa on epithelial differentiation.
Differentiation
23:
226-233,
1983[Medline].
73.
Hall, P. A.,
P. J. Coates,
B. Ansari,
and
D. Hopwood.
Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis.
J. Cell Sci.
107:
3569-3577,
1994
74.
Halttunen, T.,
A. Marttinen,
I. Rantala,
H. Kainulainen,
and
M. Maki.
Fibroblasts and transforming growth factor induce organization and differentiation of T84 human epithelial cells.
Gastroenterology
111:
1252-1262,
1996[Medline].
75.
Hawkey, C.,
A. Kahan,
K. Steinbruck,
C. Alegre,
E. Baumelou,
B. Begaud,
J. Dequeker,
H. Isomaki,
G. Littlejohn,
J. Mau,
and
S. Papazoglou.
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam large-scale international study safety assessment.
Br. J. Rheumatol.
37:
937-945,
1998[Medline]. [Corrigenda. Br. J. Rheumatol. 37: October 1998, p. 1142.]
76.
Hendel, J.,
and
O. H. Nielsen.
Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease.
Am. J. Gastroenterol.
92:
1170-1173,
1997[Medline].
77.
Hinterleitner, T. A.,
J. I. Saada,
H. M. Berschneider,
D. W. Powell,
and
J. D. Valentich.
IL-1 stimulates intestinal myofibroblast COX gene expression and augments activation of Cl secretion in T84 cells.
Am. J. Physiol.
271 (Cell Physiol. 40):
C1262-C1268,
1996
78.
Hirota, S.,
K. Isozaki,
Y. Moriyama,
K. Hashimoto,
T. Nishida,
S. Ishiguro,
K. Kawano,
M. Hanada,
A. Kurata,
M. Takeda,
T. G. Muhammad,
Y. Matsuzawa,
Y. Kanakura,
Y. Shinomura,
and
Y. Kitamura.
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science
279:
577-580,
1998
79.
Holm, L.,
and
G. Flemstrom.
Microscopy of acid transport at the gastric surface in vivo.
J. Intern. Med. Suppl.
732:
91-95,
1990[Medline].
80.
Hong, W. K.,
and
M. B. Sporn.
Recent advances in chemoprevention of cancer.
Science
278:
1073-1077,
1997
81.
Hormi, K.,
and
T. Lehy.
Transforming growth factor- in vivo stimulates epithelial cell proliferation in digestive tissues of suckling rats.
Gut
39:
532-538,
1996[Abstract].
82.
Housley, R. M.,
C. F. Morris,
W. Boyle,
B. Ring,
R. Biltz,
J. E. Tarpley,
S. L. Aukerman,
P. L. Devine,
R. H. Whitehead,
and
G. F. Pierce.
Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract.
J. Clin. Invest.
94:
1764-1777,
1994[Medline].
83.
Howe, J. R.,
S. Roth,
J. C. Ringold,
R. W. Summers,
H. J. Jarvinen,
P. Sistonen,
I. P. Tomlinson,
R. S. Houlston,
S. Bevan,
F. A. Mitros,
E. M. Stone,
and
L. A. Aaltonen.
Mutations in the SMAD4/DPC4 gene in juvenile polyposis.
Science
280:
1086-1088,
1998
84.
Huizinga, J. D.
Neural Injury, Repair and Adaptation in the GI Tract. IV. Pathophysiology of GI motility related to interstitial cells of Cajal.
Am. J. Physiol.
275 (Gastrointest. Liver Physiol. 38):
G381-G386,
1998
85.
Huizinga, J. D.,
L. Thuneberg,
M. Kluppel,
J. Malysz,
H. B. Mikkelsen,
and
A. Bernstein.
W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity.
Nature
373:
347-349,
1995[Medline].
86.
Hull, M. A.,
J. L. Brough,
D. G. Powe,
G. I. Carter,
D. Jenkins,
and
C. J. Hawkey.
Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa.
Gut
43:
525-536,
1998
87.
Hull, M. A.,
D. J. Cullen,
N. Hudson,
and
C. J. Hawkey.
Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration.
Gut
37:
610-612,
1995[Abstract].
88.
Iseki, S.
Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach.
Histochem. J.
27:
323-328,
1995[Medline].
89.
Isozaki, K.,
S. Hirota,
J. Miyagawa,
M. Taniguchi,
Y. Shinomura,
and
Y. Matsuzawa.
Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction.
Am. J. Gastroenterol.
92:
332-334,
1997[Medline].
90.
Isozaki, K.,
S. Hirota,
A. Nakama,
J. Miyagawa,
Y. Shinomura,
Z. Xu,
S. Nomura,
and
Y. Kitamura.
Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats.
Gastroenterology
109:
456-464,
1995[Medline].
91.
Jacoby, R. F.,
S. Schlack,
C. E. Cole,
M. Skarbek,
C. Harris,
and
L. F. Meisner.
A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria.
Gastroenterology
112:
1398-1403,
1997[Medline].
92.
Jain, M. K.,
M. D. Layne,
M. Watanabe,
M. T. Chin,
M. W. Feinberg,
N. E. Sibinga,
C. M. Hsieh,
S. F. Yet,
D. L. Stemple,
and
M. E. Lee.
In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells.
J. Biol. Chem.
273:
5993-5996,
1998
93.
Javed, N. H.,
Y. Z. Wang,
and
H. J. Cooke.
Neuroimmune interactions: role for cholinergic neurons in intestinal anaphylaxis.
Am. J. Physiol.
263 (Gastrointest. Liver Physiol. 26):
G847-G852,
1992
94.
Jobson, T. M.,
C. K. Billington,
and
I. P. Hall.
Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation.
J. Clin. Invest.
101:
2650-2657,
1998
95.
Joyce, N. C.,
M. F. Haire,
and
G. E. Palade.
Morphologic and biochemical evidence for a contractile cell network within the rat intestinal mucosa.
Gastroenterology
92:
68-81,
1987[Medline].
96.
Kaiser, G. C.,
and
D. B. Polk.
Tumor necrosis factor regulates proliferation in a mouse intestinal cell line.
Gastroenterology
112:
1231-1240,
1997[Medline].
97.
Kapanci, Y.,
S. Burgan,
G. G. Pietra,
B. Conne,
and
G. Gabbiani.
Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension.
Am. J. Pathol.
136:
881-889,
1990[Abstract].
98.
Kargman, S.,
S. Charleson,
M. Cartwright,
J. Frank,
D. Riendeau,
J. Mancini,
J. Evans,
and
G. O'Neill.
Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts.
Gastroenterology
111:
445-454,
1996[Medline].
99.
Kargman, S. L.,
G. P. O'Neill,
P. J. Vickers,
J. F. Evans,
J. A. Mancini,
and
S. Jothy.
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.
Cancer Res.
55:
2556-2559,
1995[Abstract].
100.
Kaye, G. I.,
N. Lane,
and
R. R. Pascal.
Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. II. Fine structural aspects of normal rabbit and human colon.
Gastroenterology
54:
852-865,
1968[Medline].
101.
Kaye, G. I.,
R. R. Pascal,
and
N. Lane.
The colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. 3. Replication and differentiation in human hyperplastic and adenomatous polyps.
Gastroenterology
60:
515-536,
1971[Medline].
102.
Kedinger, M.,
P. Simon-Assmann,
F. Bouziges,
and
K. Haffen.
Epithelial-mesenchymal interactions in intestinal epithelial differentiation.
Scand. J. Gastroenterol. Suppl.
151:
62-69,
1988[Medline].
103.
Keely, S. J.,
W. A. Stack,
D. P. O'Donoghue,
and
A. W. Baird.
Regulation of ion transport by histamine in human colon.
Eur. J. Pharmacol.
279:
203-209,
1995[Medline].
104.
Kim, E. C.,
Y. Zhu,
V. Andersen,
D. Sciaky,
H. J. Cao,
H. Meekins,
T. J. Smith,
and
P. Lance.
Cytokine-mediated PGE2 expression in human colonic fibroblasts.
Am. J. Physiol.
275 (Cell Physiol. 44):
C988-C994,
1998
105.
Kindblom, L.-G.,
J. M. Meis-Kindblom,
H. E. Remotti,
and
F. Aldenborg.
Gastrointestinal pacemaker cell tumor: GI-pact (Abstract).
Mod. Pathol.
11:
A65,
1998.
106.
Kindon, H.,
C. Pothoulakis,
L. Thim,
K. Lynch-Devaney,
and
D. K. Podolsky.
Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein.
Gastroenterology
109:
516-523,
1995[Medline].
107.
Kinoshita, Y.,
H. Nakata,
S. Hassan,
M. Asahara,
C. Kawanami,
Y. Matsushima,
Y. Naribayashi-Inomoto,
C. Y. Ping,
D. Min,
and
A. Nakamura.
Gene expression of keratinocyte and hepatocyte growth factors during the healing of rat gastric mucosal lesions.
Gastroenterology
109:
1068-1077,
1995[Medline].
108.
Kinzler, K. W.,
and
B. Vogelstein.
Landscaping the cancer terrain.
Science
280:
1036-1037,
1998
109.
Klimpel, G. R.,
K. E. Langley,
J. Wypych,
J. S. Abrams,
A. K. Chopra,
and
D. W. Niesel.
A role for stem cell factor (SCF): c-kit interaction(s) in the intestinal tract response to Salmonella typhimurium infection.
J. Exp. Med.
184:
271-276,
1996[Abstract].
110.
Komuro, T.
Three-dimensional observation of the fibroblast-like cells associated with the rat myenteric plexus, with special reference to the interstitial cells of Cajal.
Cell Tissue Res.
255:
343-351,
1989[Medline].
111.
Komuro, T.,
and
Y. Hashimoto.
Three-dimensional structure of the rat intestinal wall (mucosa and submucosa).
Arch. Histol. Cytol.
53:
1-21,
1990[Medline].
112.
Kunz, D.,
G. Walker,
W. Eberhardt,
U. K. Messmer,
A. Huwiler,
and
J. Pfeilschifter.
Platelet-derived growth factor and fibroblast growth factor differentially regulate interleukin 1- and cAMP-induced nitric oxide synthase expression in rat renal mesangial cells.
J. Clin. Invest.
100:
2800-2809,
1997
113.
Lane, N.,
H. Kaplan,
and
R. R. Pascal.
Minute adenomatous and hyperplastic polyps of the colon: divergent patterns of epithelial growth with specific associated mesenchymal changes. Contrasting roles in the pathogenesis of carcinoma.
Gastroenterology
60:
537-551,
1971[Medline].
114.
Lawson, L. D.,
and
D. W. Powell.
Bradykinin-stimulated eicosanoid synthesis and secretion by rabbit ileal components.
Am. J. Physiol.
252 (Gastrointest. Liver Physiol. 15):
G783-G790,
1987
115.
Leibl, M. A.,
T. Ota,
M. N. Woodward,
S. E. Kenny,
D. A. Lloyd,
C. R. Vaillant,
and
D. H. Edgar.
Expression of endothelin 3 by mesenchymal cells of embryonic mouse caecum.
Gut
44:
246-252,
1999
116.
Lieubeau, B.,
L. Garrigue,
I. Barbieux,
K. Meflah,
and
M. Gregoire.
The role of transforming growth factor 1 in the fibroblastic reaction associated with rat colorectal tumor development.
Cancer Res.
54:
6526-6532,
1994[Abstract].
117.
Liu, L.,
J. R. Turner,
Y. Yu,
A. J. Khan,
R. Jaszewski,
S. E. G. Fligiel,
and
A. P. N. Majumdar.
Differential expression of EGFR during early reparative phase of the gastric mucosa between young and aged rats.
Am. J. Physiol.
275 (Gastrointest. Liver Physiol. 38):
G943-G950,
1998
118.
Liu, Q.,
X. X. Du,
D. T. Schindel,
Z. X. Yang,
F. J. Rescorla,
D. A. Williams,
and
J. L. Grosfeld.
Trophic effects of interleukin-11 in rats with experimental short bowel syndrome.
J. Pediatr. Surg.
31:
1047-1050,
1996[Medline].
119.
Lu, X.,
W. Xie,
D. Reed,
W. S. Bradshaw,
and
D. L. Simmons.
Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts.
Proc. Natl. Acad. Sci. USA
92:
7961-7965,
1995[Abstract].
120.
Lund, B.,
M. Distel,
and
E. Bluhmki.
A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee.
Scand. J. Rheumatol.
27:
32-37,
1998[Medline].
121.
MacDonald, T. T.,
and
S. L. Pender.
Proteolytic enzymes in inflammatory bowel disease.
Inflamm. Bowel. Dis.
4:
157-164,
1998[Medline].
122.
Mahida, Y. R.,
J. Beltinger,
S. Makh,
M. Goke,
T. Gray,
and
D. K. Podolsky.
Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2.
Am. J. Physiol.
273 (Gastrointest. Liver Physiol. 36):
G1341-G1348,
1997
123.
Mameya, S.,
T. Sawa,
and
K. Taniyama.
Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin-1 in guinea pig ileum.
J. Pharmacol. Exp. Ther.
275:
319-324,
1995[Abstract].
124.
Marcus, A. J.
Aspirin as prophylaxis against colorectal cancer.
N. Engl. J. Med.
333:
656-658,
1995
125.
Markowitz, S.,
J. Wang,
L. Myeroff,
R. Parsons,
L. Sun,
J. Lutterbaugh,
R. S. Fan,
E. Zborowska,
K. W. Kinzler,
and
B. Vogelstein.
Inactivation of the type II TGF- receptor in colon cancer cells with microsatellite instability.
Science
268:
1336-1338,
1995[Medline].
126.
Markowitz, S. D.
Atherosclerosis, just another cancer?
J. Clin. Invest.
100:
2143-2145,
1997
127.
Marsh, M. N.,
and
J. S. Trier.
Morphology and cell proliferation of subepithelial fibroblasts in adult mouse jejunum. II. Radioautographic studies.
Gastroenterology
67:
636-645,
1974[Medline].
128.
Martens, M. F.,
C. M. Huyben,
and
T. Hendriks.
Collagen synthesis in fibroblasts from human colon: regulatory aspects and differences with skin fibroblasts.
Gut
33:
1664-1670,
1992[Abstract].
129.
Martin, M.,
P. Pujuguet,
and
F. Martin.
Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion.
Pathol. Res. Pract.
192:
712-717,
1996[Medline].
130.
McKaig, B. C.,
S. S. Makh,
C. J. Hawkey,
D. K. Podolsky,
and
Y. R. Mahida.
Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-3.
Am. J. Physiol.
276 (Gastrointest. Liver Physiol. 39):
G1087-G1093,
1999
131.
Miller, S. M.,
G. Farrugia,
P. F. Schmalz,
L. G. Ermilov,
M. D. Maines,
and
J. H. Szurszewski.
Heme oxygenase 2 is present in interstitial cell networks of the mouse small intestine.
Gastroenterology
114:
239-244,
1998[Medline].
132.
Mizuno, H.,
C. Sakamoto,
K. Matsuda,
K. Wada,
T. Uchida,
H. Noguchi,
T. Akamatsu,
and
M. Kasuga.
Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice.
Gastroenterology
112:
387-397,
1997[Medline].
133.
Moore, R.,
S. Carlson,
and
J. L. Madara.
Villus contraction aids repair of intestinal epithelium after injury.
Am. J. Physiol.
257 (Gastrointest. Liver Physiol. 20):
G274-G283,
1989
134.
Morgan, G.
Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.
Gut
38:
646-648,
1996[Medline].
135.
Mourelle, M.,
A. Salas,
F. Guarner,
E. Crespo,
A. Garcia-Lafuente,
and
J. R. Malagelada.
Stimulation of transforming growth factor 1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis.
Gastroenterology
114:
519-526,
1998[Medline].
136.
Muhl, H.,
and
J. Pfeilschifter.
Amplification of nitric oxide synthase expression by nitric oxide in interleukin 1-stimulated rat mesangial cells.
J. Clin. Invest.
95:
1941-1946,
1995[Medline].
137.
Naftalin, R. J.,
and
K. C. Pedley.
Regional crypt function in rat large intestine in relation to fluid absorption and growth of the pericryptal sheath.
J. Physiol. (Lond.)
514:
211-227,
1999
138.
Naftalin, R. J.,
P. S. Zammit,
and
K. C. Pedley.
Regional differences in rat large intestinal crypt function in relation to dehydrating capacity in vivo.
J. Physiol. (Lond.)
514:
201-210,
1999
139.
Nakahara, M.,
K. Isozaki,
S. Hirota,
J. Miyagawa,
N. Hase-Sawada,
M. Taniguchi,
T. Nishida,
S. Kanayama,
Y. Kitamura,
Y. Shinomura,
and
Y. Matsuzawa.
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.
Gastroenterology
115:
1090-1095,
1998[Medline].
140.
Nakamura, M.,
M. Oda,
J. Inoue,
T. Ito,
Y. Akiba,
M. Kitajima,
M. Tsuchiya,
and
H. Ishii.
Plasticity of myofibroblasts appearing in granulation tissues after acetic acid treatment. Effect of bFGF.
Dig. Dis. Sci.
40:
2477-2480,
1995[Medline].
141.
Nakamura, M.,
M. Oda,
Y. Nishizaki,
K. Kaneko,
T. Azuma,
and
M. Tsuchiya.
Fluorescent histochemical study on the localization of myofibroblasts in the healing of acetic acid-induced gastric ulcers in the rat.
Scand. J. Gastroenterol. Suppl.
162:
150-153,
1989[Medline].
142.
Neal, J. V.,
and
C. S. Potten.
Description and basic cell kinetics of the murine pericryptal fibroblast sheath.
Gut
22:
19-24,
1981[Abstract].
143.
Nusrat, A.,
C. A. Parkos,
A. E. Bacarra,
P. J. Godowski,
C. Delp-Archer,
E. M. Rosen,
and
J. L. Madara.
Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium.
J. Clin. Invest.
93:
2056-2065,
1994[Medline].
144.
Ogawa, M.,
Y. Matsuzaki,
S. Nishikawa,
S. Hayashi,
T. Kunisada,
T. Sudo,
T. Kina,
and
H. Nakauchi.
Expression and function of c-kit in hemopoietic progenitor cells.
J. Exp. Med.
174:
63-71,
1991[Abstract].
145.
Orazi, A.,
X. Du,
Z. Yang,
M. Kashai,
and
D. A. Williams.
Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation.
Lab. Invest.
75:
33-42,
1996[Medline].
146.
Oshima, M.,
J. E. Dinchuk,
S. L. Kargman,
H. Oshima,
B. Hancock,
E. Kwong,
J. M. Trzaskos,
J. F. Evans,
and
M. M. Taketo.
Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Cell
87:
803-809,
1996[Medline].
147.
Pang, G.,
L. Couch,
R. Batey,
R. Clancy,
and
A. Cripps.
GM-CSF, IL-1, IL-1, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 and TNF.
Clin. Exp. Immunol.
96:
437-443,
1994[Medline].
148.
Pascal, R. R.,
G. I. Kaye,
and
N. Lane.
Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. I. Autoradiographic studies of normal rabbit colon.
Gastroenterology
54:
835-851,
1968[Medline].
149.
Pasricha, P. J.,
A. Bedi,
K. O'Connor,
A. Rashid,
A. J. Akhtar,
M. L. Zahurak,
S. Piantadosi,
S. R. Hamilton,
and
F. M. Giardiello.
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.
Gastroenterology
109:
994-998,
1995[Medline].
150.
Pedley, K. C.,
and
R. J. Naftalin.
Evidence from fluorescence microscopy and comparative studies that rat, ovine and bovine colonic crypts are absorptive.
J. Physiol. (Lond.)
460:
525-547,
1993[Abstract].
151.
Pelet, A.,
O. Geneste,
P. Edery,
A. Pasini,
S. Chappuis,
T. Atti,
A. Munnich,
G. Lenoir,
S. Lyonnet,
and
M. Billaud.
Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
J. Clin. Invest.
101:
1415-1423,
1998
152.
Peterson, C. A.,
D. M. Ney,
P. S. Hinton,
and
H. V. Carey.
Beneficial effects of insulin-like growth factor I on epithelial structure and function in parenterally fed rat jejunum.
Gastroenterology
111:
1501-1508,
1996[Medline].
153.
Peterson, J. W.,
and
L. G. Ochoa.
Role of prostaglandins and cAMP in the secretory effects of cholera toxin.
Science
245:
857-859,
1989[Medline].
154.
Planchon, S. M.,
C. A. Martins,
R. L. Guerrant,
and
J. K. Roche.
Regulation of intestinal epithelial barrier function by TGF-1. Evidence for its role in abrogating the effect of a T cell cytokine.
J. Immunol.
153:
5730-5739,
1994
155.
Plateroti, M.,
D. C. Rubin,
I. Duluc,
R. Singh,
C. Foltzer-Jourdainne,
J.-N. Freund,
and
M. Kedinger.
Subepithelial fibroblast cell lines from different levels of gut axis display regional characteristics.
Am. J. Physiol.
274 (Gastrointest. Liver Physiol. 37):
G945-G954,
1998
156.
Playford, R. J.,
and
N. A. Wright.
Why is epidermal growth factor present in the gut lumen?
Gut
38:
303-305,
1996[Abstract].
157.
Polk, D. B.
Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity.
Gastroenterology
114:
493-502,
1998[Medline].
158.
Potten, C. S.,
G. Owen,
D. Hewitt,
C. A. Chadwick,
H. Hendry,
B. I. Lord,
and
L. B. Woolford.
Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.
Gut
36:
864-873,
1995[Abstract].
159.
Powell, D. W.
Immunophysiology of intestinal electrolyte transport.
In: Handbook of Physiology. The Gastrointestinal System. Intestinal Absorption and Secretion. Bethesda, MD: Am. Physiol. Soc., 1991, sect. 6, vol. IV, chapt. 25, p. 591-641.
160.
Powell, D. W.
Dogma destroyed: colonic crypts absorb.
J. Clin. Invest.
96:
2102-2103,
1995[Medline].
161.
Powell, D. W.
Water transport revisited.
J. Physiol. (Lond.)
514:
1,
1999
162.
Powell, D. W.,
and
H. M. Berschneider.
Mesenchymal-epithelial interactions: the subepithelial fibroblastic sheath as a paracrine modulator of inflammation-induced intestinal secretion.
In: Immunophysiology of the Gut, edited by W. A. Walker. San Diego, CA: Academic, 1993, p. 25-42.
163.
Powell, D. W.,
R. C. Mifflin,
J. D. Valentich,
S. E. Crowe,
J. I. Saada,
and
A. B. West.
Myofibroblasts. I. Paracrine cells important in health and disease.
Am. J. Physiol.
277 (Cell Physiol. 46):
C1-C19,
1999
164.
Prescott, S. M.,
and
R. L. White.
Self-promotion? Intimate connections between APC and prostaglandin H synthase-2.
Cell
87:
783-786,
1996[Medline].
165.
Pujuguet, P.,
A. Hammann,
F. Martin,
and
M. Martin.
Abnormal basement membrane in tumors induced by rat colon cancer cells.
Gastroenterology
107:
701-711,
1994[Medline].
166.
Pujuguet, P.,
A. Hammann,
M. Moutet,
J. L. Samuel,
F. Martin,
and
M. Martin.
Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts.
Am. J. Pathol.
148:
579-592,
1996[Abstract].
167.
Reinecker, H. C.,
R. P. MacDermott,
S. Mirau,
A. Dignass,
and
D. K. Podolsky.
Intestinal epithelial cells both express and respond to interleukin 15.
Gastroenterology
111:
1706-1713,
1996[Medline].
168.
Reuter, B. K.,
S. Asfaha,
A. Buret,
K. A. Sharkey,
and
J. L. Wallace.
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.
J. Clin. Invest.
98:
2076-2085,
1996
169.
Richman, P. I.,
and
W. F. Bodmer.
Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions.
J. Pathol.
156:
197-211,
1988[Medline].
170.
Riegler, M.,
R. Sedivy,
T. Sogukoglu,
E. Cosentini,
G. Bischof,
B. Teleky,
W. Feil,
R. Schiessel,
G. Hamilton,
and
E. Wenzl.
Epidermal growth factor promotes rapid response to epithelial injury in rabbit duodenum in vitro.
Gastroenterology
111:
28-36,
1996[Medline].
171.
Roberts, A. I.,
S. C. Nadler,
and
E. C. Ebert.
Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes.
Gastroenterology
113:
144-150,
1997[Medline].
172.
Robertson, K.,
I. Mason,
and
S. Hall.
Hirschsprung's disease: genetic mutations in mice and men.
Gut
41:
436-441,
1997
173.
Rumessen, J. J.
Ultrastructure of interstitial cells of Cajal at the colonic submuscular border in patients with ulcerative colitis.
Gastroenterology
111:
1447-1455,
1996[Medline].
174.
Rungger-Brandle, E.,
and
G. Gabbiani.
The role of cytoskeletal and cytocontractile elements in pathologic processes.
Am. J. Pathol.
110:
361-392,
1983[Medline].
175.
Saada, J. I.,
J. Valentich,
D. W. Powell,
and
S. E. Crowe.
Myofibroblast differentiation and the regulation of intestinal ion transport (Abstract).
Gastroenterology
112:
A398,
1997.
176.
Sanders, K. M.
A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract.
Gastroenterology
111:
492-515,
1996[Medline].
177.
Sandler, R. S.,
J. C. Galanko,
S. C. Murray,
J. F. Helm,
and
J. T. Woosley.
Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas.
Gastroenterology
114:
441-447,
1998[Medline].
178.
Sappino, A. P.,
P. Y. Dietrich,
O. Skalli,
S. Widgren,
and
G. Gabbiani.
Colonic pericryptal fibroblasts. Differentiation pattern in embryogenesis and phenotypic modulation in epithelial proliferative lesions.
Virchows Arch. A Pathol. Anat. Histopathol.
415:
551-557,
1989[Medline].
179.
Sawaoka, H.,
S. Kawano,
S. Tsuji,
M. Tsujii,
E. S. Gunawan,
Y. Takei,
K. Nagano,
and
M. Hori.
Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice.
Am. J. Physiol.
274 (Gastrointest. Liver Physiol. 37):
G1061-G1067,
1998
180.
Schmassmann, A.,
C. Stettler,
R. Poulsom,
N. Tarasova,
C. Hirschi,
B. Flogerzi,
K. Matsumoto,
T. Nakamura,
and
F. Halter.
Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats.
Gastroenterology
113:
1858-1872,
1997[Medline].
181.
Schmitt-Graff, A.,
A. Desmouliere,
and
G. Gabbiani.
Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity.
Virchows Arch.
425:
3-24,
1994[Medline].
182.
Sheng, G. G.,
J. Shao,
H. Sheng,
E. B. Hooton,
P. C. Isakson,
J. D. Morrow,
R. J. J. Coffey,
R. N. DuBois,
and
R. D. Beauchamp.
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.
Gastroenterology
113:
1883-1891,
1997[Medline].
183.
Shiff, S. J.,
and
B. Rigas.
Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions.
Gastroenterology
113:
1992-1998,
1997[Medline].
184.
Shigematsu, T.,
S. Miura,
M. Hirokawa,
R. Hokari,
H. Higuchi,
N. Watanabe,
Y. Tsuzuki,
H. Kimura,
S. Tada,
R. C. Nakatsumi,
H. Saito,
and
H. Ishii.
Induction of endothelin-1 synthesis by IL-2 and its modulation of rat intestinal epithelial cell growth.
Am. J. Physiol.
275 (Gastrointest. Liver Physiol. 38):
G556-G563,
1998
185.
Simon, L. S.,
F. L. Lanza,
P. E. Lipsky,
R. C. Hubbard,
S. Talwalker,
B. D. Schwartz,
P. C. Isakson,
and
G. S. Geis.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Arthritis Rheum.
41:
1591-1602,
1998[Medline].
186.
Simon-Assmann, P.,
M. Kedinger,
A. De Arcangelis,
V. Rousseau,
and
P. Simo.
Extracellular matrix components in intestinal development.
Experientia
51:
883-900,
1995[Medline].
187.
Singer, I. I.,
D. W. Kawka,
S. Schloemann,
T. Tessner,
T. Riehl,
and
W. F. Stenson.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Gastroenterology
115:
297-306,
1998[Medline].
188.
Sircar, K.,
B. Hewlett,
and
R. H. Riddell.
Most gastrointestinal stromal tumors (GIST) arise from interstitial cells of Cajal (ICC) (Abstract).
Lab. Invest.
78:
71A,
1998.
189.
Smith, R. L.,
and
D. W. Powell.
Prolonged treatment of Menetrier's disease with an oral anticholinergic drug.
Gastroenterology
74:
903-906,
1978[Medline].
190.
Smits, R.,
W. van der Houven van Oordt,
A. Luz,
C. Zurcher,
S. Jagmohan-Changur,
C. Breukel,
P. M. Khan,
and
R. Fodde.
Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts.
Gastroenterology
114:
275-283,
1998[Medline].
191.
Sottili, M.,
C. Sternini,
M. Reinshagen,
N. C. Brecha,
C. C. Nast,
J. H. Walsh,
and
V. E. Eysselein.
Up-regulation of transforming growth factor alpha binding sites in experimental rabbit colitis.
Gastroenterology
109:
24-31,
1995[Medline].
192.
Souza, R. F.,
J. Lei,
J. Yin,
R. Appel,
T. T. Zou,
X. Zhou,
S. Wang,
M. G. Rhyu,
K. Cymes,
O. Chan,
W. S. Park,
M. J. Krasna,
B. D. Greenwald,
J. Cottrell,
J. M. Abraham,
L. Simms,
B. Leggett,
J. Young,
N. Harpaz,
and
S. J. Meltzer.
A transforming growth factor 1 receptor type II mutation in ulcerative colitis-associated neoplasms.
Gastroenterology
112:
40-45,
1997[Medline].
193.
Strong, S. A.,
T. T. Pizarro,
J. S. Klein,
F. Cominelli,
and
C. Fiocchi.
Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells.
Gastroenterology
114:
1244-1256,
1998[Medline].
194.
Synnerstad, I.,
E. Ekblad,
F. Sundler,
and
L. Holm.
Gastric mucosal smooth muscles may explain oscillations in glandular pressure: role of vasoactive intestinal peptide.
Gastroenterology
114:
284-294,
1998[Medline].
195.
Takahashi, M.,
S. Ota,
Y. Hata,
Y. Mikami,
N. Azuma,
T. Nakamura,
A. Terano,
and
M. Omata.
Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach.
J. Clin. Invest.
98:
2604-2611,
1996
196.
Takahashi, S.,
J. I. Shigeta,
H. Inoue,
T. Tanabe,
and
S. Okabe.
Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats.
Am. J. Physiol.
275 (Gastrointest. Liver Physiol. 38):
G1137-G1145,
1998
197.
Tetsuka, T.,
D. Daphna-Iken,
S. K. Srivastava,
L. D. Baier,
J. DuMaine,
and
A. R. Morrison.
Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1.
Proc. Natl. Acad. Sci. USA
91:
12168-12172,
1994
198.
Tiitta, O.,
P. Sipponen,
V. Gould,
and
I. Virtanen.
Tenascin expression in inflammatory, dysplastic and neoplastic lesions of the human stomach.
Virchows Arch.
425:
369-374,
1994[Medline].
199.
Torihashi, S.,
W. T. Gerthoffer,
S. Kobayashi,
and
K. M. Sanders.
Identification and classification of interstitial cells in the canine proximal colon by ultrastructure and immunocytochemistry.
Histochemistry
101:
169-183,
1994[Medline].
200.
Torihashi, S.,
S. M. Ward,
S. Nishikawa,
K. Nishi,
S. Kobayashi,
and
K. M. Sanders.
c-Kit-dependent development of interstitial cells and electrical activity in the murine gastrointestinal tract.
Cell Tissue Res.
280:
97-111,
1995[Medline].
201.
Torihashi, S.,
S. M. Ward,
and
K. M. Sanders.
Development of c-Kit-positive cells and the onset of electrical rhythmicity in murine small intestine.
Gastroenterology
112:
144-155,
1997[Medline].
202.
Toyoda, H.,
K. Ina,
H. Kitamura,
T. Tsuda,
and
T. Shimada.
Organization of the lamina propria mucosae of rat intestinal mucosa, with special reference to the subepithelial connective tissue.
Acta Anat. (Basel)
158:
172-184,
1997[Medline].
203.
Tsujii, M.,
and
R. N. DuBois.
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.
Cell
83:
493-501,
1995[Medline].
204.
Tsushima, H.,
S. Kawata,
S. Tamura,
N. Ito,
Y. Shirai,
S. Kiso,
Y. Imai,
H. Shimomukai,
Y. Nomura,
Y. Matsuda,
and
Y. Matsuzawa.
High levels of transforming growth factor 1 in patients with colorectal cancer: association with disease progression.
Gastroenterology
110:
375-382,
1996[Medline].
205.
Valentich, J. D.,
V. Popov,
J. I. Saada,
and
D. W. Powell.
Phenotypic characterization of an intestinal subepithelial myofibroblast cell line.
Am. J. Physiol.
272 (Cell Physiol. 41):
C1513-C1524,
1997
206.
Valentich, J. D.,
and
D. W. Powell.
Interleukin-1 (IL-1) treatment of a myofibroblast-like cell line (18Co) enhances sensitization of juxtaposed T84 cells to secretagogues (Abstract).
Gastroenterology
106:
A278,
1994.
207.
Valentich, J. D.,
and
D. W. Powell.
Intestinal subepithelial myofibroblasts and mucosal immunophysiology.
Curr. Opin. Gastroenterol.
10:
645-651,
1994.
208.
Vanderwinden, J. M.,
H. Liu,
M. H. De Laet,
and
J. J. Vanderhaeghen.
Study of the interstitial cells of Cajal in infantile hypertrophic pyloric stenosis.
Gastroenterology
111:
279-288,
1996[Medline].
209.
Vanderwinden, J. M.,
J. J. Rumessen,
H. Liu,
D. Descamps,
M. H. De Laet,
and
J. J. Vanderhaeghen.
Interstitial cells of Cajal in human colon and in Hirschsprung's disease.
Gastroenterology
111:
901-910,
1996[Medline].
210.
Vane, J. R.,
Y. S. Bakhle,
and
R. M. Botting.
Cyclooxygenases 1 and 2.
Annu. Rev. Pharmacol. Toxicol.
38:
97-120,
1998[Medline].
211.
Van Tol, E. A. F.,
L. Holt,
F. L. Li,
F.-M. Kong,
R. Rippe,
M. Yamauchi,
J. Pucilowska,
P. K. Lund,
and
R. B. Sartor.
Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts.
Am. J. Physiol.
277 (Gastrointest. Liver Physiol. 40):
G245-G255,
1999
212.
Wallace, J. L.
Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.
Gastroenterology
112:
1000-1016,
1997[Medline].
213.
Wallace, J. L.,
A. Bak,
W. McKnight,
S. Asfaha,
K. A. Sharkey,
and
W. K. MacNaughton.
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
Gastroenterology
115:
101-109,
1998[Medline].
214.
Wallace, J. L.,
and
D. N. Granger.
The cellular and molecular basis of gastric mucosal defense.
FASEB J.
10:
731-740,
1996
215.
Wang, J.,
W. Niu,
Y. Nikiforov,
S. Naito,
S. Chernausek,
D. Witte,
D. LeRoith,
A. Strauch,
and
J. A. Fagin.
Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice.
J. Clin. Invest.
100:
1425-1439,
1997
216.
Wang, L.,
S. Savedia,
M. Benjamin,
and
M. H. Perdue.
The role of mast cells in intestinal immunophysiology.
Adv. Exp. Med. Biol.
371:
287-292,
1995.
217.
Ward, S. M.,
A. J. Burns,
S. Torihashi,
S. C. Harney,
and
K. M. Sanders.
Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants.
Am. J. Physiol.
269 (Cell Physiol. 38):
C1577-C1585,
1995
218.
Ward, S. M.,
G. Morris,
L. Reese,
X. Y. Wang,
and
K. M. Sanders.
Interstitial cells of Cajal mediate enteric inhibitory neurotransmission in the lower esophageal and pyloric sphincters.
Gastroenterology
115:
314-329,
1998[Medline].
219.
Warhurst, G.,
N. B. Higgs,
A. Tonge,
and
L. A. Turnberg.
Stimulatory and inhibitory actions of carbachol on chloride secretory responses in human colonic cell line T84.
Am. J. Physiol.
261 (Gastrointest. Liver Physiol. 24):
G220-G228,
1991
220.
Wester, T.,
L. Eriksson,
Y. Olsson,
and
L. Olsen.
Interstitial cells of Cajal in the human fetal small bowel as shown by c-kit immunohistochemistry.
Gut
44:
65-71,
1999
221.
Williams, C. B.
Discouraging colonic polyps.
Gut
40:
430,
1997
222.
Williams, C. S.,
C. Luongo,
A. Radhika,
T. Zhang,
L. W. Lamps,
L. B. Nanney,
R. D. Beauchamp,
and
R. N. DuBois.
Elevated cyclooxygenase-2 levels in Min mouse adenomas.
Gastroenterology
111:
1134-1140,
1996[Medline].
223.
Williams, C. S.,
W. Smalley,
and
R. N. DuBois.
Aspirin use and potential mechanisms for colorectal cancer prevention.
J. Clin. Invest.
100:
1325-1329,
1997
224.
Womack, W. A.,
P. R. Kvietys,
and
D. N. Granger.
Villous motility.
In: Handbook of Physiology. The Gastrointestinal System. Motility and Circulation. Bethesda, MD: Am. Physiol. Soc., 1989, sect. 6, vol. I, pt. 2, chapt. 25, p. 975-986.
225.
Xue, C.,
J. Pollock,
H. Schmidt,
S. M. Ward,
and
K. M. Sanders.
Expression of nitric oxide synthase immunoreactivity by interstitial cells of the proximal colon.
J. Auton. Nerv. Syst.
49:
1-14,
1994[Medline].
226.
Yamasaki, K.,
H. D. J. Edington,
C. McClosky,
E. Tzeng,
A. Lizonova,
I. Kovesdi,
D. L. Steed,
and
T. R. Billiar.
Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer.
J. Clin. Invest.
101:
967-971,
1998
227.
Yao, T.,
and
M. Tsuneyoshi.
Significance of pericryptal fibroblasts in colorectal epithelial tumors: a special reference to the histologic features and growth patterns.
Hum. Pathol.
24:
525-533,
1993[Medline].
228.
Yashiro, M.,
Y. S. Chung,
T. Kubo,
F. Hato,
and
M. Sowa.
Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts.
Br. J. Cancer
74:
1096-1103,
1996[Medline].
229.
Young, H. M.,
D. Ciampoli,
B. R. Southwell,
and
D. F. Newgreen.
Origin of interstitial cells of Cajal in the mouse intestine.
Dev. Biol.
180:
97-107,
1996[Medline].
230.
Zeeh, J. M.,
F. Procaccino,
P. Hoffmann,
S. L. Aukerman,
J. A. McRoberts,
S. Soltani,
G. F. Pierce,
J. Lakshmanan,
D. Lacey,
and
V. E. Eysselein.
Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats.
Gastroenterology
110:
1077-1083,
1996[Medline].
231.
Zeroogian, J. M.,
and
S. Chopra.
Collagenous colitis and lymphocytic colitis.
Annu. Rev. Med.
45:
105-118,
1994[Medline].
232.
Zimmermann, E. M.
Intestinal fibrosis in inflammatory bowel disease.
Regul. Pept.
7:
60-63,
1997.